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Abstract 
 
Introduction  
Human Immuno-deficiency Virus (HIV) infection and Sexually Transmitted Infections (STIs) 
are important transmittable infections in the world. They are transmitted mostly through sexual 
activity and contaminated blood exchange (needle). Key populations are the most affected 
groups in the world from these infections, one of the important key population is female sex 
worker (FSW). Although FSW is the most vulnerable group, stigma, discrimination, poverty 
and less evidence-based policy have been the reasons this group cannot get access to health 
care. Endocervical infections or also called cervicitis is common among FSW. This infection 
is commonly caused by Neissheria gonorrhoea and Chlamydia trachomatis, although infection 
of Mycoplasma genitalium in endocervix is also quite common. This study investigated the 
sensitivity and specificity of current test, the correlation between prevalence of endocervical 
infections with behavior and other routine test result among women working in entertainment 
venues in Jayapura. Aims of this study are to evaluate current STI-HIV screening test and to 
generate some recommendations for stakeholders. 
Material and methods 
This study was using questionnaire which was adapted from several studies about FSW 
behaviour, and one of this study was conducted on a national scope, the Integrated Biological 
and Behavioural Survey (IBBS) in 2011. The laboratory result was from routine screening test 
in the reproduction health centre (PKR) and additional PCR test for N. gonorrhoeae and C. 
trachomatis on endocervical sample. Participants of this study are women working in 
entertainment venues in Jayapura-Papua, Indonesia for at least three months. 
Results 
Among 176 participants who got tested for any endocercival test of N. gonorrhoea and C. 
trachomatis, 24.4 percent (n = 43) of participant had at least one endocervical infection. Among 
all participants, the percentage of STIs was 26.5 percent (n=50). On bivariate analysis; Age, 
marriage status, last education, number of clients in the last week, have standard education, 
have regular sexual male partner in the last 1 year, have history of vaginal discharge in the last 
5 year, have regular HIV check, use hotel and or rent room/ working place as a place of sexual 
transaction were associated with any endocervical infection.  
iv 
 
On multiple logistic regression analysis age, marriage status and a past history of vaginal 
discharge are significantly related to any endocervical infection among participants. 
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Abbreviation 
 
AIDS Acquired immune deficiency syndrome 
ART Antiretroviral treatment  
ARV  Antiretroviral 
BID Two times daily 
BV Bacterial vaginosis 
cART Combination of antiretroviral 
CI Confidence interval 
CoC Combination of oral contraception  
CTNG Chlamydia trachomatis and Neissheria gonorrhoeae 
DMPA Depot Medroxyprogesterone Acetate 
DNA Deoxyribonucleic Acid  
EIA  Enzyme-linked immunosorbent assay  
FK-LKB Forum koordinasi-layanan komprehensif HIV-IMS 
berkesinambungan  
FSW Female sex worker 
GC Gonorrhoea culture  
HAART Highly active antiretroviral therapy 
Hb Haemoglobin 
HIV  Human immunodeficiency virus  
HPV Human papillomavirus  
HRM High-risk man 
HSV Herpes simplex virus  
IBBS Integrated biological and behavioural survey 
IDU Injecting drug user  
IUD Intrauterine device 
KOH Potassium hydroxide 
KUHP Kitab undang-undang hukum pidana 
LARC Long-acting reversible contraception  
LGV  Lymphogranuloma venerum  
MSM Men who have sex with men 
NAAT Nucleic Acid Amplification Test 
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NCNGU Non-chlamydial non-gonorrhoeae urethritis 
NGO Non-governmental organisation  
NPV Negative predictive value 
PcP Pneumocystis carinii pneumonia  
PCR Polymerase Chain Reaction 
PEP Post-exposure prophylaxis 
PID Pelvic inflammatory disease 
PKR Pusat Kesehatan Reproduksi (Reproduction Health Center) 
PMNL Polymorphonuclear Leukocyte 
PNG Papua new-guinea 
PPT Periodic presumptive therapy 
PPV Positive predictive value 
PrEP Pre-exposure prophylaxis 
PWID People who inject drugs 
RNA Ribonucleic acid 
RPR Rapid plasma reagin 
STI Sexually transmitted infection  
TB Tuberculosis 
UNAIDS Joint United Nations Programme on HIV/AIDS 
VCT Voluntary counselling and testing  
VDRL Venereal Disease Research Laboratory  
WHO World Health Organisation 
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Chapter I 
1. Introduction 
 
This thesis presents findings from a cross-sectional descriptive study that investigated 
the prevalence of sexually transmitted infections (STI) and human immunodeficiency 
virus (HIV) and documented STI/HIV-related behaviour among women working in 
entertainment venues in Jayapura City, Indonesia. This chapter presents background 
information about the global, regional and local epidemiology of STI and HIV and the 
history of sex work in Papua. The aims and significance of the study are explained and 
the organisation of this thesis is outlined. 
 
1.1 Background 
 
Sexually transmitted infections (STI) and human immunodeficiency virus (HIV) are 
still important global public health issues (1,2). In 2012, the World Health Organization 
(WHO) estimated that there were 357.4 million new cases (approximately 1 million per 
day) of four curable STIs - chlamydia, gonorrhoea, syphilis and trichomoniasis (Table 
1.1.1) (2,3). Globally, robust WHO data show a downward trend in syphilis infection. 
Trends in the other three infections are difficult to establish because of changes in 
estimation methodology between surveys. Viral STI infections remain very high, with 
417 million cases of herpes simplex infection and 291 million cases of human 
papillomavirus (2).   
Table 1.1.1  
Estimated Incidence of STI  in 2012 (2) 
Sexually Transmitted Infection  n (million) 
Chlamydia trachomatis 130.9 
Neisseria gonorrhoeae 78.3 
Treponema pallidum 5.6 
Trichomonas vaginalis 142.6 
Total 357.4 
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In 2015, there were approximately 36.7 (34.0-39.8) million people living with HIV, 
with 2.1 (95% CI, 1.8-2.4) million new cases worldwide. Sub-Saharan Africa was the 
most affected region; in 2015 it had 25.6 (95% CI, 23.1-28.5) million people living with 
HIV and accounted for two-thirds of all new HIV infections. Indonesia accounted for 
3.6% of global HIV incidence (4). 
 
Only 60% of HIV-infected individuals in the world are aware of their status. The 
remaining 40% remain unaware for various reasons - they have not been tested for fear 
of stigma and discrimination or other factors, there is no HIV testing facility available 
in the area, they do not have enough information about the importance of HIV testing, 
or they struggle to gain access to testing (1,5,6). Although there is no cure for HIV, 
effective antiretroviral (ARV) treatment can suppress viral replication, limit adverse 
clinical outcomes and prevent transmission (7). As a result of advances in ARV, from 
2000 to 2015, new infections dropped by 35% and AIDS-related deaths declined by 
28%, saving 8 million lives (1). 
 
 
Up-to-date epidemiological data on STIs in the general population of Indonesia are 
limited. The 2014 National Health Profile, published by the Ministry of Health in 2015, 
only provides data on HIV incidence (8). According to this database, which collected 
information from all healthcare facilities with responsibility for HIV/STI services, the 
number of new HIV cases increased significantly, from 21,511 cases in 2012 to 29,037 
in 2013, reaching its peak in 2014 (32,711 cases) (8).  
 
Nonetheless, STI data are available from several studies of key populations. One of 
these sources is the Integrated Biological and Behavioural Survey (IBBS) which was 
conducted in 2011 on at-risk populations including female sex workers (FSW); men 
who have sex with men (MSM); high-risk men (HRM) such as truck drivers, ojek 
(moto-taxi) drivers, seafarers and dock workers; injecting drug users (IDU) who are 
now referred to as people who inject drugs (PWID); transgender individuals (waria); 
and youth (9). These data show that, apart from HIV, the rates of other STIs are quite 
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high among FSW (Table 1.1.2). The prevalences of HIV (serological), syphilis 
(serological), gonorrhoea (microscopy) and chlamydia (NAAT) were 10.4%, 10.2%, 
37.8% and 40.7%, respectively, among direct FSW (i.e. those who work primarily to 
sell sex). Among indirect FSW (those, typically in the entertainment/hospitality 
industry, for whom sex trading is not the core business but can be a source of 
supplementary income), the prevalences were 2.9%, 3.1%, 18.7%, 40.6 %, respectively 
(9). 
 
Table 1.1.2  
Prevalence of Curable STIs in  Key Populations (n=17,486) (9)   
Population HIV Gonorrhoea 
 
Chlamydia Gonorrhoea 
or 
Chlamydia 
or both 
Syphilis 
Direct FSW 
(n=3793) 
10.4 % 37.8 % 40.7 % 56.5 % 10.2 % 
Indirect FSW 
(n=3149) 
2.9 % 18.7 % 40.6 % 48.6 % 3.1 % 
MSM (n=1244) 8.5 % 20.8 % 20.5 % 32.8 % 9.3 % 
Transgender (waria) 
(n=1072) 
21.9 % 28.8 % 28.3 % 42.8 % 25.3 % 
HRM (n=4844) 0.7 % No data No data No data 4.4 % 
Prisoners (n=1965) 3.0 % No data No data No data 4.8 % 
IDU (n=1419) 36.4 % No data No data No data 2.1 % 
 
Previously, several smaller studies had examined STIs among FSW in Indonesia. In 
2005, a study was conducted in 9 provinces (10 cities) with a sample of nearly 2,500 
(10). The overall STI rate among FSW was 64%, with prevalence rates for chlamydia, 
gonorrhoea, trichomoniasis and syphilis of 43.5%, 28.6%, 15.1% and 8.7%, 
respectively (10). Among the nine provinces, Central Java province had the highest 
prevalence of chlamydia, followed by West Java and East Java (10). In 2007, another 
study of 5,947 FSW reported rates of HIV, syphilis, gonorrhoea and chlamydia of 
10.6%, 35.6%, 31.8%, and 7.3%, respectively, among direct FSW, and 4.9%, 28.7%, 
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14.3% and 3.5%, respectively, among indirect FSW (11). STIs in these key populations 
in Indonesia can be summarised as follows: gonorrhoea and chlamydia infection rates 
are high among FSW, syphilis is high among transgender, while HIV is highest among 
IDU (9,12). 
 
Previously, HIV/AIDS was managed locally by district governments. Since 2006, 
however, it has been recognised as a national problem and is monitored by the central 
government under the direction of the Social Affairs Minister. In 1994, the President 
announced the formation of the first National AIDS Commission (Policy No. 39-1994). 
The first national AIDS countermeasures strategy was initiated in June of that year (13).  
 
 
 
Jayapura City is the capital of Papua province (Figure 1.1.1). It has an area of 
14,390,155 km2 and a population of approximately  143,848 (in 2014) (14). Jayapura 
District was a single entity before 1993 when a separate administration for Jayapura 
City was created. Then in 2002, Jayapura District was expanded to include two other 
areas, Sarmi, and Keerom. Together, Jayapura City and Jayapura District make up 
modern Jayapura. 
Over the last 30 years, Jayapura has become the main transport and entertainment centre 
in Papua. It is the transit point for travel to other parts of Papua through Sentani Airport, 
the Province’s main airport. Keerom and Sarmi are connected to Jayapura City and 
Jayapura District by land transport links. Compared to Jayapura, other areas in Papua 
are minimally served by leisure facilities.  
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Figure 1.1.1 Map of Papua Province   
 
Sex work activity is not criminalised in Indonesia. Neither clients nor sex workers can 
be prosecuted unless the sexual activity involves underage persons (below 17 years 
under the Child Protection Law) (15). Soliciting customers for a sex worker or brothel, 
however, is illegal under anti‐trafficking legislation (no.  21/2007), which bans all 
forms of human trafficking including sexual exploitation (16). In the past, brothel areas 
called lokasi were created by the government of Indonesia in most provinces, allowing 
the government to exercise administrative control over the brothel owner and the sex 
worker. In some provinces, local regulations maintain greater restrictions or even ban 
sex work in certain areas (17). For example in 2015, the brothel area in Jayapura was 
closed down by the local government and direct sex work ceased to be controlled by 
the government. As a result, most of the former direct sex workers are now engaged in 
indirect sex work.  
Rates of STI and HIV are increasing significantly in Papua despite the implementation 
of various strategies at different levels of the health system. Limited surveillance data 
and resources, as well as the absence of evidence-based policies, are two of the key 
challenges facing policy-makers and clinicians in the province. Women working in 
entertainment venues are one of the most important ‘at risk’ populations in Jayapura.  
This is particularly so now, following closure of the brothel area in 2015 and the shift 
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of employees from direct to indirect sex work and street sex work. Reducing the 
prevalence of STI and HIV in this high-risk group would make an important 
contribution to a reduction in both incidence and prevalence in the general population. 
The findings from the present study will add to the limited prevalence data on 
molecular-based chlamydia and gonorrhoea, inform the improvement of clinical 
services and contribute to the future development of a screening model using NAATs 
for chlamydia and gonorrhoea. 
 
1.2 Aims and Significance of the Study 
The study had three main aims: 
 To report the prevalence of HIV, syphilis, chlamydia, gonorrhoea, and 
trichomoniasis among women working in entertainment venues in Jayapura; 
 To determine which demographic, clinical and behavioural risks are associated 
with the detection of any chlamydia and/or gonorrhoea infection in the 
endocervix. 
 To assess the sensitivity of the current Gram staining, compared to the NAAT-
based gold standard, for the detection of gonorrhoea in women attending the 
Reproduction Health Centre (PKR) clinic in Jayapura. 
The study was based in a clinic that undertakes routine screening of women working in 
the entertainment industry. The clinic performs a limited number of routine tests, 
including serology HIV and syphilis, Gram staining of cervical and vaginal specimens 
for gonorrhoea, bacterial vaginosis (BV) and candidiasis, as well as wet film 
microscopical examination for Trichomonas vaginalis.  
For this study, an additional test - the Nucleic Acid Amplification Test (NAAT) for 
chlamydia and gonorrhoea - was performed to determine the prevalence of these two 
important STIs among women attending the clinic. NAAT-based endocervical infection 
screening provides a more accurate estimate of the prevalence of genital gonorrhoea, 
given that Gram-stained microscopy is usually only about 40-50% sensitive (at best) in 
detecting gonococcal endocervical infection in women. 
The study also examined demographic, clinical and behavioural risk factors associated 
with the acquisition of endocervical STIs. 
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The results provide previously unavailable data that can inform policy decisions in 
relation to a potential model for NAAT test screening among women working in 
entertainment venues. Since these tests are expensive, it is important that they are used 
to screen those women most at risk of gonorrhoea and chlamydia. 
 
1.3 Organisation of the Thesis 
This chapter has introduced the study and explained its background, aims and 
significance. Chapter 2 presents a detailed review of scientific literature relevant to the 
study’s focus on STI/HIV, including aetiology, signs and symptoms, diagnostic 
procedures and treatment regimens. Chapter 3 describes the methods that were used to 
collect and analyse data and discusses the ethical considerations involved in the study. 
Chapter 4 presents the results from analysis of the behavioural and clinical data. These 
results are discussed in Chapter 5, with a particular focus on the correlations between 
key variables, implications of the study, and recommendations for practice and future 
research. 
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Chapter 2 
2. Literature Review 
 
This chapter presents more about STI-HIV epidemiology, key population in Indonesia, and 
widely discuss basic science of STI-HIV. This basic science highlight clinical features, 
diagnosis, and treatment of HIV and each STI including syndromic management.  
 
2.1 HIV-STI Global Epidemiology 
 
HIV infection is a major worldwide public health issue, mainly because there is as yet no way 
of eradicating the virus from infected individuals or preventing its acquisition through 
vaccination (18). The HIV infection damages the host’s immune system, making the person 
susceptible to secondary infection from another organism such as tuberculosis (TB), oral 
candidiasis or Pneumocistic carinii pneumonia (PCP) (19). This immune system failure can 
lead to the development of Acquired Immune Deficiency Syndrome (AIDS), which results in 
morbidity or even death. Combination antiretroviral drug therapy (ARV) has been shown to 
inhibit viral replication and help to improve HIV-AIDS patients’ quality of life (20,21). 
 
The first case of AIDS was reported in 1981 among a cluster of injection drug users (IDUs) 
and men who have sex with men (MSM) (19). This group of patients had impaired immunity 
and were diagnosed with Pneumocystis carinii pneumonia (PCP). The number of cases then 
increased sharply each year. In 1984, HIV was identified as the cause of AIDS (22,21,19). This 
infection has since spread all over the world (13).  
 
In 2015, nearly 36.7 (95% CI, 34.0-39.8) million people were living with HIV.2 worldwide. In 
that year, 100,000 (95% CI, 1.8-2.4) people were newly infected, which represented a reduction 
from the 3.1 million and 2.7 million cases reported for 2001 and 2010, respectively (23,24). 
Only 60% of people living with HIV in 2015 knew their status; the remaining 40% (nearly 14 
million) had not been in contact with any HIV testing service. By mid-2016, only around 18.2 
million people living with HIV around the world were receiving ARV (23). 
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The population groups at highest risk vary among regions of the world. People who inject drugs 
accounted for 51% of people living with HIV in Eastern Europe and Central Asia. The MSM 
population accounts for 49% of infected persons in Western and Central Europe and North 
America, and 30% in Latin America and the Caribbean. Clients of sex workers and other sexual 
partners of at-risk populations make up the greatest number living with HIV in the Middle East 
and North Africa (25).  
 
Between 2000 and 2015, the number of new HIV infections fell by 35% and AIDS-related 
deaths declined by 28%, thus saving an estimated 8 million lives. To date, HIV has claimed 35 
million lives and, in 2015, 1.1 (95% CI, 940.000-1.3) million people around the world died 
from HIV-related causes (23). Sub-Saharan Africa is by far the most seriously affected region 
in relation to HIV infections, with 25.6 (23.1-28.5) million people living with HIV in 2015 
(23). Sub-Saharan Africa also accounts for two-thirds of new HIV infections (26). 
 
 
Our ability to compare surveillance data between countries is limited by variability in case 
definitions and completeness of reporting. It is estimated that more than 1 million sexually 
transmitted infections (STIs) are acquired worldwide every day. The majority of STIs might 
not be recognised as such because they have mild or no symptoms. Each year, WHO estimates 
that there are 357 million new infections of four curable STIs - chlamydia (131 million), 
gonorrhoea (78 million), syphilis (5.6 million) and trichomoniasis (143 million) (2). In relation 
to viral STIs, WHO estimates that there are around 417 million cases of herpes simplex virus 
(HSV) and that 291 million women have acquired human papillomavirus (HPV) (2). Among 
high-risk populations, FSWs and MSM are most affected, with high rates of syphilis 
seroprevalence among both groups (2). 
According to UNAIDS data, an estimated 5.1 million (95% CI, 4.4 – 5.9 million) people are 
living with HIV in the Asia-Pacific region (27). Indonesia ranked highest among all countries 
in the South East Asian region (27).  
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2.2 HIV-STI Epidemiology in Indonesia 
 
In Indonesia, all HIV-AIDS prevalence and incidence data from all districts and cities should 
be reported to provincial health departments. Provincial staff then pools the reports and pass 
them to the Indonesian Ministry of Health. The first AIDS case in Indonesia occurred in 1987.  
In 2009, the Indonesian Ministry of Health estimated that around 186,257 people were living 
with HIV in Indonesia. The latest estimates by UNAIDS (2015) show a significant increase, 
up to 690,000 (95% CI, 600,000-790,000), based on the assumption that the number of cases 
notified in 2009 (73,078) represents the tip of the iceberg, or 30% of actual cases. In December 
2010, there were 24,131 cases of AIDS in Indonesia and 55,848 reported cases of HIV (28).  
 
 
Figure 2.2.1 HIV prevalence map of Indonesia 
According to 2009 estimates by the Indonesian Department Health, 33 provinces and 300 
districts/cities reported prevalence rates of HIV and AIDS in their areas (Figure 2.2.1). HIV 
prevalence is concentrated among high-risk groups (>5%), compared to the estimated HIV 
prevalence of around 0.2% in the general adult population (28). In the two most easterly 
provinces of Indonesia, Papua and West Papua, the adult HIV prevalence rate in the general 
population is approximately 2.4% (28). 
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From the beginning of 1990 until early 2000, HIV was predominantly transmitted by needle 
use among drug users. Sexual transmission, however, is now the main form of transmission in 
both the homosexual and heterosexual populations (28). The number of females living with 
HIV in Indonesia is increasing every year, creating a shift from a male-dominated to a female-
dominated epidemic (28).  Of all women living with HIV, the highest prevalence is not among 
FSW or PWID but among housewives, followed by FSWs and then professional women (28). 
This situation might indicate silent transmission among heterosexual couples and an increase 
in the number of screenings that occur during antenatal care. 
 
 
Only limited epidemiological and other data on STIs in the general Indonesian population are 
available according to the 2014 National Health Profile, published by the Ministry of Health 
of Indonesia in 2015 (8). Nonetheless, several studies have collected data on key populations. 
In 2011, for instance, the Integrated Biology and Behaviour Survey (IBBS) collected data on 
female sex workers (FSW), men who have sex with men (MSM), high-risk men (HRM) such 
as truck drivers, ojek (moto-taxi) drivers, seafarers and dock workers, injecting drug users 
(IDU), transgender persons (waria), and youth (9). These data show that, apart from HIV, the 
rates of other STIs are quite high among FSW. The prevalences of HIV, syphilis, gonorrhoea 
and chlamydia were 10.4%, 10.2%, 37.8% and 40.7%, respectively, among direct FSW (i.e. 
those who work primarily to sell sex). Among indirect FSW (those typically working in bars, 
clubs, karaoke bars and massage parlours, for whom sex trading is not the core business but 
can be a source of supplementary income), the prevalences were 2.9%, 3.1%, 18.7%, 40.6 %, 
respectively (9). 
Previously, several smaller studies had examined STIs among FSW in Indonesia. In 2005, a 
study was conducted in 9 provinces (10 cities) with a sample of nearly 2,500 (10). The overall 
STI rate among FSW was 64%, with prevalence rates for chlamydia, gonorrhoea, 
trichomoniasis and syphilis of 43.5%, 28.6%, 15.1% and 8.7%, respectively (10). Among the 
nine provinces, Central Java province had the highest prevalence of chlamydia, followed by 
West Java and East Java (10). In 2007, another study of 5,947 FSW reported rates of HIV, 
syphilis, gonorrhoea and chlamydia of 10.6%, 35.6%, 31.8%, and 7.3%, respectively, among 
direct FSW, and 4.9%, 28.7%, 14.3% and 3.5%, respectively, among indirect FSW (11). In 
relation to viral STI, a small survey was conducted of female clients at two mother and child 
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clinics in Bali, as well as clients (male and female) of two obstetrics and gynaecology clinics 
in Makasar, two dermatovenereology clinics in Bali and two in Makasar. The rates of herpes 
simplex type 2 antibodies found in these populations are shown in Table 2.2.1. 
 
Table 2.2.1 
 Prevalence of Herpes Simplex Type 2 Antibodies in Several Populations of Indonesia (29) 
 
 
STIs in these key populations in Indonesia can be summarised as follows: gonorrhoea and 
chlamydia infection rates are high among FSW, syphilis is high among MSM, transgender, and 
queer, while HIV is highest among IDU (9,12). 
 
2.3 HIV/STI in Papua 
 
The first HIV case in Papua was identified in 1992 in Merauke. It was predicted that, by 2013, 
the prevalence of HIV in the population would be 5%. IBBS data for 2013, however, showed 
the prevalence to be around 2.4%. 
Previously, in 2002 it was estimated that there are 20.4 cases per 100,000 people which was 
far greater when compared with the other areas in Indonesia that had an average of 0.42 cases 
per 100,000 people (30). Nearly, almost half (40%) of the HIV and AIDS cases in Indonesia at 
that time were located in Papua (which contains less than 1% of the Indonesian population) 
(30). In 2006 IBBS’s data revealed 26% of HIV rates among commercial FSW (31). In the 
same survey the rate of HIV seroprevalence was 2.4% in general population (31). Since the roll 
out of free ART started in 2003, it is estimated that ART is accessed by approximately 24% of 
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patients with advanced HIV, and access may be as low as 3% in Papua. In 2010, 141 of 162 
(87%) smear-positive tuberculosis (TB) patients were offered voluntary counselling and testing 
(VCT) (31). Among this population of HIV-infected TB patients, 14 out of 67 Papuans (21%) 
were HIV positive compared to 4 out of 71 non-Papuans (5.6%). Papuan women seemed to 
have a higher risk for HIV co-infection compared to men (31). Clinical characteristic of TB + 
/HIV +  patients include lower tolerance on exercise as well as a significant decrease in both 
of mean haemoglobin (Hb) and white cell count (31). 
Table 2.1.3 shows the number of reported cases of HIV/AIDS in Papua province between 1992 
and 2013 (22). From 2003, the figures exclude West Papua province. Although there was a 
rapid increase in cases of both HIV and AIDS, the increase in AIDS cases was more consistent. 
Possible reasons for the fluctuating figures for HIV include late detection, rejection of 
treatment and failure to follow up treatment. Over this period, there were 1,076 AIDS-related 
deaths in Papua. 
 
HIV-AIDS countermeasures were officially initiated in Papua in 1998, four years after the first 
National AIDS Commission was established in Indonesia (22). In 1998 a workgroup was 
assembled under Irian Jaya (as Papua was formerly known) Province Health Service, then in 
2001, the National AIDS Commission was formed in Papua province (22).  
 
Table 2.3.1 
HIV and AIDS Cases in Papua Province 1992-2013 (22) 
 
Reporting year AIDS HIV Total 
1992 0 6 6 
1993 1 49 50 
1994 4 2 6 
1995 8 4 12 
1996 4 6 10 
1997 3 3 6 
1998 23 8 31 
1999 23 47 70 
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2000 90 92 182 
2001 33 136 169 
2002 100 169 269 
2003 103 217 3,200 
2004 119 334 453 
2005 331 355 686 
2006 519 208 727 
2007 822 257 1,079 
2008 987 313 1,300 
2009 1,215 642 1,857 
2010 1,352 888 2,240 
2011 1,479 923 2,402 
2012 1,488 862 2,350 
2013 1,082 603 1,685 
Unknown 76 64 140 
Total 9,862 6,188 16,050 
 
 
 
Generally, in Papua, STIs remain high every year among the high-risk population. In Timika- 
Papua, between 1997 and 2002, the rate of STIs among FSW were remained high despite some 
decreasing numbers of some infections (32). In this period, gonorrhoea and trichomoniasis 
fluctuated from 18.4% and 16.1% in 1997 to 19% and 13.6% in 2002, respectively. In the same 
study the number syphilis infections were below 5% (32). In Jayapura city in 2015, based on 
the report of Reproductive Health Center (PKR) the rates of STI among female sex worker 
were 2,440 cases of trichomoniasis and 1,242 cases of cervicitis (33).  
 
Papua New Guinea (PNG) is a direct neighbour country of Papua (Indonesia). Papua and PNG 
share one island with a political line dividing the two countries. There are several border posts 
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along the line and one of them is located in Jayapura City region. The border posts are where 
the movement of people from one country to another could happen through land migration. 
Human migration has an impact on the transfer of sexually transmitted infections. Given that 
STIs rarely give an obvious symptom like high fever, except in sepsis, it is unlikely that STI 
patients will be detected through thermal scanning at the border.  
A study in 1984 using a retrospective method revealed 10 years (1974-1983) of government 
records (34). During this period 101,636 gonorrhoea cases and 34,422 syphilis were reported 
among the PNG population (34). In 1989, a study was conducted in several STD clinics in Port 
Moresby, Goroka, Rabaul, Lae and Daru (35). This multicenter study reported a 26% (54/210) 
and 27% (17/64) C. trachomatis positivity among males and females, respectively, using direct 
immunofluorescence (35). On culture-based testing, ten percent (21/210) of males and eleven 
percent (7/64) of females were gonorrhoea positive and on serological test, five percent 
(10/203) of males and twelve percent (9/78) of females were positive for syphilis (35). 
In 2004 UNAIDS published a PNG Epidemiology fact sheets which reported 4% of syphilis in 
highland population, with a much higher rate (32%) among FSW and a moderately higher 
prevalence among pregnant women attending antenatal services (7.1%). For chlamydia, a 
prevalence of 26% was reported in the highland population, with 31% among FSW. For 
gonorrhoea, a 15% prevalence was reported from the highland population with 36% among 
FSW. Trichomonas vaginalis was detected in  28.75% of FSW (36). 
Another multicentre study, conducted in 2010, reported prevalence data for gonorrhoea, 
chlamydia, trichomoniasis and syphilis were 33.6%, 26.1%, 39.3% and 33.1%, respectively, in 
FSW population (37). HIV rate in this study was pooled at 1.8% in men, 2.6% in women, and 
11.8% among FSW (37).   
The HIV epidemic in PNG is similar to Papua (Indonesia), namely a generalised epidemic with 
more than 1% people aged 15 to 49 years living with HIV-infected acquired predominantly by 
heterosexual transmission (36). The first HIV case in PNG was found in 1987; subsequently, 
the prevalence increased significantly to reach 18,484 cases in 2006 (36). The prevalence rate 
among the general population aged between 15 to 49 years was 1.28% nationally and 1.32 in 
rural area. The prevalence of rural infections is important as 85% of the PNG population lives 
in rural areas. At the present moment, the rising trend for HIV prevalence is expected to 
increase significantly in coming years (36).  
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2.4 Key Populations  
 
The story of sex work is as old as the story of ancient Indonesian kingdoms. In the past, all 
kings and regional leaders (who were chosen by the king or the colonial government) had the 
right to have as many mistresses as they wished (38). In the 1600s, women were not treated as 
individuals but as commodities that could be offered to strengthen relationships or as tribute 
(38). This gender inequality, along with poverty, were the main contributing factors to the 
development of sex work in Indonesia (38). 
The first civilian brothel in Indonesia was opened in Jakarta (the capital city, previously known 
as Batavia) in 1943 by a Japanese man, Washio Awochi, during the Japanese military 
occupation of the country. Although he was a civilian,  the Japanese military was involved in 
running this particular brothel (39). Because this type of work is highly stigmatised and 
condemned by the majority of the population, the government has tried to confine such 
activities to specific areas, separate from residential and business areas. Most brothels in 
Indonesia are located in such specified areas.  
The Indonesian government does not have any specific legislation about sex work. Several 
laws - on adultery (the Bill on the Criminal Code/KUHP No. 296 and 506), child protection 
(the Act, year 2002 No. 23) and human trafficking (the Act, year 2007 No. 21) – are used by 
law enforcement agencies not to regulate the activity, but to criminalise those involved in sex 
work (16). These laws allow police to prosecute those who arrange sex business (‘pimps’) or 
derive benefit from any sex work activities outside brothel areas (human trafficking) (16).  
Any sex work activity inside a localised brothel area is legal. Neither clients nor providers can 
be prosecuted unless underage (less than 18 years) individuals are involved or the activity takes 
place outside the designated area. In some provinces, however, local laws have been created to 
further restrict or even abolish the legal sex work industry. For example in Aceh, West Java 
and East Java some local brothel areas were closed by the government in response to religious 
and moral concerns. 
In relation to indirect sex work, there are strict government bans on sex work activities in 
massage parlours, clubs and bars. If such activities are detected, the police and local 
government will close the business down. Nonetheless, the government, including the 
government in Papua, provides free STI checks for female staff in entertainment venues and 
  
17 
 
requires management to have their employees checked at the STI clinic at their own expense. 
This clearly suggests that the government is aware of sex activities within these premises but 
denies they exist to avoid public perception that it supports sex work. 
In Papua, localised brothels emerged in 1976 when concerns about illegal prostitution in public 
spaces (40) led to the relocation of some of the brothels to a new area in East Sentani suburb. 
This area is subject to monthly inspections by the government to control the spread of infection 
and maintain the health of local sex workers (40). The sex workers in Papua come from various 
provinces in Indonesia, particularly from Java and Sulawesi; only a small percentage are from 
Papua (17). They total around 300 women (33). 
The uncontrolled increase in numbers of sex workers and a shortage of health practitioners, 
however, has meant that the government has found it difficult to supervise the brothel area 
effectively (40). In 2000, the prevalence of positive gonorrhoea infection was around 25% in 
the brothel area. In August 2015, the brothel area in Papua province (Tanjung Elmo) was closed 
by the local government following political pressure from the central government and local 
communities. 
 
According to WHO, the HIV epidemic among MSM group is re-emerging. The median 
prevalence of HIV in this group ranges from 4.3% in South East Asia to 14.9% in Africa (41). 
MSM are the most stigmatised group in Indonesia (42). Based on national data, it was estimated 
that the population of MSM in Indonesia was around 766,390 in 2006 (43). They are mostly 
found in the large cities, with many migrating to urban areas from rural communities, where 
they have received serious threats; this is particularly common among members of some tribes 
in Papua (22). These men face rejection, discrimination or even death if their sexual orientation 
becomes public knowledge (22). Many MSM try to work as drag queens or live as transvestites 
in order to gain community acceptance. This violence and stigma compromise their right to 
access health care, including HIV services. In Indonesia, several MSM support groups have 
been established by NGOs. One such group, Yayasan Embun Pelangi, seeks to connect MSM 
with health care providers. 
 
People who inject drugs (PWID) are a recognised high-risk group for HIV acquisition. It is 
estimated by the Ministry of Health that Indonesia is home to 74,000 injecting drug users (44). 
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In 2015, Indonesian national drug enforcement pledged to send 100,000 drug users, including 
those who inject, to rehabilitation (44). In the early 1990s, PWID had the highest HIV 
prevalence among all high-risk groups (44) but by 2014 PWID accounted for only 15% of HIV 
cases in Indonesia (44). They are mainly located in cities and urban areas because of the 
availability of drugs and injection equipment.  
 
Young people account for more than one-quarter of Indonesia’s population (45). In 2010, it 
was estimated that there were some 237,641 15-29 year-olds (44). The largest segment was 
aged 25-29 years and there were more males than females (44). Indonesian youth are 
considered to be a high-risk group for acquiring HIV and STI (45). This is attributed to the 
very young ages at which marriage often occurs. Among ever-married women between 20 to 
24 years, for instance, 25% were married before the age of 17 (45), and the rate of child 
marriage in rural areas is around 10%% (45).  
 
Transgender (‘waria) in Indonesia is a term for “males who typically live as women and take 
men as lovers“(46). Since the independence of Indonesia in 1945, there has been no specific 
law that prohibits people with the same gender to have sex, except in the state penal code 
someone can get caught if the activity includes young individual below 17 years old (46).  
Transgender (‘waria’) is the initiator of LGBT movements in Indonesia. There has been a lot 
of struggle and stigmas on this group especially from religious group (47). They struggled to 
get a job and predominantly gathered together and build a business in beauty salon to survive. 
Given these situation, waria is usually struggled to get access to health care, despite quite a 
high risk sexual (anal) activities they have(47). 
 
2.5 HIV-STI Clinical Features in Women 
 
The clinical features of HIV do not differ significantly between women and men. (18).  
Clinical manifestations of primary HIV infection are (18):  
 96% fever  
 74% lymphadenopathy  
 70% pharyngitis  
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 70% rash  
 54% myalgia 
 32% diarrhea 
 32% headache 
 27% nausea and vomiting 
 14% hepatosplenomegaly 
 13% weight loss 
 12% oral candida 
 12% neurological symptoms.  
Most women would not be aware that they had been infected by HIV. Some might experience 
flu-like symptoms (tiredness, headache, fever and enlarged lymph nodes) as the infection 
develops and the immune system is affected. The first sign of HIV infection is enlargement of 
the lymph nodes (‘swollen glands’), which might persist for more than 3 months. The other 
AIDS symptoms, common to males and females, include: 
 Fatigue 
 Weight loss 
 Night sweats with low-grade fever 
 Skin rashes. 
Other symptoms specific to women include: 
 Vaginal yeast infection  
 Infection of reproductive organs or menstrual cycle changes such as amenorrhea.  
Almost all aspects of gynaecological care for women with HIV are the same as those for healthy 
women. Some adjustments need to be considered in relation to contraception to ensure there is 
no interference with HIV treatment. Some modifications are also indicated in relation to 
screening, treatment and follow-up for cervical cancer and infection around the genitalia, 
including human papillomavirus (HPV), herpes simplex virus (HSV) and candida, since these 
conditions and infections might recur more frequently or be more severe in women with HIV 
(18). 
In relation to cervical cancer prevention, cervical screening among HIV-infected women aged 
25 years or over is recommended if it has not been performed in the last 12 months. Some 
guidelines recommend baseline colposcopy (if resources are available) to avoid false negative 
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cervical smear results, prior to regular cytological monitoring (48). This is because HIV 
infection can boost the risk of both cervical cancer and cervical intraepithelial neoplasia (CIN) 
and appears to be associated with immunosuppression (49). CIN is frequently (20-40%) 
detected in women with HIV and this might increase (up to 80%) if the CD4 counts go below 
200 cells/uL (49).  
There are several considerations regarding the choice of contraception for women with HIV 
(18). First, they should be supported to make an informed choice of the most effective 
contraception method (18). This information should include failures rates, principal side effects 
and the benefits of a dual contraceptive approach (employing condoms to prevent HIV/STI 
acquisition and adding a second contraceptive method to ensure an extremely low risk of 
pregnancy) (18). Second, drug interaction is important; hepatic enzyme-inducing drugs, 
including some combination antiretroviral therapies (cART), are likely to interfere with the 
efficacy of combined oral contraceptives (COCs). Progesterone-only pills should be avoided 
unless used in combination with condoms (50). The relationship between Depo-Provera 
(DMPA) and abnormal liver function is not very clear (18). Therefore, consistent use of 
condoms in conjunction with any other contraceptive method is strongly recommended. 
Among all the methods of contraception, long acting reversible contraception (LARC) is the 
most effective reversible mode of contraception in combination with condoms (18). 
 
2.5.2.1 Vaginal discharge  
Vaginal discharge is one of the most common STI symptoms which require an accurate 
diagnosis before giving treatment and advice (49,51). Although vaginal discharge has  mostly 
pathological causes (bacterial vaginosis, candida and STIs), some non-pathological conditions 
can also cause vaginal discharge (49). Physiological discharge is a condition in which the 
vaginal discharge is considered a normal condition. Physiological discharge is usually caused 
by age, hormones and local factors (malignancy, postpartum, menstruation). Other less 
common causes of vaginal discharge are corpus alienum (tampon), cervical ectropion or 
endocervical polyp, chemical irritation, IUD, allergic vaginitis, trauma and fistula (rectovaginal 
or vesicovaginal) (49).  
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Vaginal discharge in STI varies depending on the cause of infection. The clinical manifestation 
of each infection is unique and can sometimes be treated by a symptomatic approach 
(syndromic management). The principal causes of vaginal discharge are: 
2.5.2.1.1 Bacterial vaginosis 
Bacterial vaginosis (BV) (Figure 2.4.1) is not categorised as an STI (49). However, it can 
increase the risk of acquisition and co-presentation of STI in the genital area (49). BV is 
common in women of childbearing age and is caused by an increasing number of anaerobic 
organisms with concentrations up to a thousand-fold which overwhelm the normal bacteria in 
the vagina (Lactobacilli spp.), increasing pH up to 7.0 (normal vaginal pH =;3.5 – 4.5) (49). 
The clinical features are (49):  
 Sharp fishy-smelling discharge 
 Thin, homogenous discharge 
 Smell is more noticeable around menstruation or following unprotected sexual 
intercourse. 
 
Figure 2.5.1 Bacterial vaginosis  
(Source: http://mcwhealthcare.com/bacterial-vaginosis/) 
 
2.5.2.1.2 Candidiasis  
This is an infection caused by Candida albicans (Figure 2.4.2). Some 25% of women have 
vaginal colonisation but only a minority experiences symptoms. Acquisition through sexual 
activities is rarely important. However, physical trauma during sexual intercourse may prompt 
an episode in a predisposed person (49). Predisposing factors include (49): 
 Broad spectrum antibiotic 
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 Estrogen surge (pregnancy and high-dose combined oral contraceptive) 
 Diabetes mellitus 
 Dermatosis (e.g. eczema) 
 Immunosuppression (HIV, steroid therapy) 
 Vaginal douching, bubble bath, shower gel, tight clothing 
Clinical features are (49):  
 Curdy white discharge 
 Smell is ‘yeasty’ but not unpleasant 
 Itching, redness and soreness around vagina and vulva 
 Fissures and excoriations might appear. 
  
Figure 2.5.2 Microscopic appearance of Candida albicans  
(Source: http://microbeonline.com) 
 
2.5.2.1.3 Trichomoniasis 
Trichomoniasis cases are the most curable of all STIs (52). The responsible parasite is 
Trichomonas vaginalis (Figure 2.4.3). Common in many tropical countries, this STI can be 
carried for several weeks before symptoms appear (49). Clinical features are (49): 
 May produce offensive smell 
 Thin homogenous yellow or green discharge 
 May increase vaginal pH 
 Strawberry cervix appearance 
 Itching and soreness. 
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Figure 2.5.3 Microscopic appearance of Trichomonas vaginalis  
(Source: http://www.aafp.org/afp/2011/0401/p807.html) 
 
2.5.2.1.4 Cervicitis  
Cervicitis (Figure 2.4.4) can be caused by chlamydial, gonococcal, mycoplasma and genital 
herpes (primary HSV) infections (49,51). Although cervicitis is usually asymptomatic, 
untreated cervicitis can have more severe consequences such as infertility and pelvic 
inflammatory disease. For this type of infection, history and physical exam cannot rule out the 
diagnosis and testing should ideally be performed (49). 
 
In 2011 the Indonesian Minister of Health published guidelines for STI management and 
explained several risk factors for acquiring cervicitis, including (43): 
 Age < 21 years old (or 25 in some places) 
 Not married 
 Had more than 1 sexual partner in the last 3 months 
 Had new sexual partners in the last 3 months 
 Any partners contracting STI 
 Lack of experience with using condoms. 
Clinical features (49): 
 Mucopurulent discharge, which may be white, yellow or green and may be 
bloodstained 
 Discharge might also be associated with intermenstrual and postcoital bleeding  
 Contact bleeding during sample swab from the cervix or coital is common 
 No itching or soreness 
 Rarely produces smell. 
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Figure 2.5.4 Cervicitis on speculum inspection  
(Source: http://www.slideshare.net/drterd/pelvic-inflammatory-disease-2619056) 
 
Table 2.4.1 summarises the differential diagnosis of the principal causes of abnormal vaginal 
discharge. Other less common causes are discussed below. 
 
Table 2.5.1  
Differential Diagnosis of the Principal Causes of Abnormal Vaginal Discharge 
Symptoms and 
signs 
Candidiasis Bacterial 
vaginosis 
Trichomoniasis Cervicitis* 
Itching or soreness ++ - +++ - 
Smell  Maybe ‘yeasty.' Offensive, fishy May be offensive - 
Colour  White White or yellow Yellow or green White or yellow 
or green 
Consistency  Curdy  Thin, homogenous Thin, homogenous Mucoid 
pH <4.5 4.5 - 7 4.5 - 7 Any 
Confirmed by  Microscopy 
and culture  
Microscopy Microscopy, 
culture  
Microscopy, 
NAAT test. 
*Cervicitis may be caused by infections such as chlamydia, gonorrhoea, HSV and Mycoplasma 
genitalium.  
 
Causes of cervicitis :  
 Chlamydia  
  
25 
 
Chlamydia trachomatis (Figure 2.4.5) is a Gram-negative, obligate intracellular pathogen. 
Humans may be infected by different C. trachomatis serovars:  
 Trachoma (serovars A, B, Ba and C) causing trachoma which leads to blindness 
 Genital biovars (serovars D-K) causing cervicitis and  urethritis 
 Lymphogranuloma venereum (LGV) biovars (serovars L1-L3).  
Chlamydia infection (serovars D-K) is the most common STI in all countries especially in 
developed and high-income countries (1). With the highest prevalence among young people 
under 25 years, the infection is often asymptomatic (70%) but can have serious sequelae 
including infertility and ectopic pregnancy if left untreated (2).  
 
 
Figure 2.5.5 Chlamydia trachomatis inclusion bodies (brown) in a McCoy cell culture  
(Source: http://phil.cdc.gov/phil/home.asp) 
 
Some studies indicate that C. trachomatis can produce both urethral and endocervical 
infections (73-76%), endocervical infections alone (15-16%) and urethral infections alone (10-
11%).  
 Gonorrhoea 
Gonorrhoea (Figure 2.4.6) is a STI caused by Gram-negative diplococcus Neisseria 
gonorrhoeae (53). It can infect the urethra, Skene’s and Bartholin’s glands, the endocervix and 
the upper reproductive tract. 
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Figure 2.5.6 Microscopic appearance of N. gonorrhoeae (arrow) in Gram stained pustular 
exudate (Source: http://textbookofbacteriology.net/neisseria.html) 
 
 Herpes simplex virus 
Genital herpes simplex virus (HSV) infection  is a common condition due to either HSV-1 or 
HSV-2 (49). These viruses, especially HSV-1, are transmitted through oro-genital contact. 
HSV-1 is now the most common cause of herpes genitalis (18) but HSV-2 is more recurrent (4 
times a year) than HSV-1 (49). The infection starts with an incubation period (5-14 days); the 
virus then enters the distal axonal processes of the sensory nerve, goes down to the sensory 
(dorsal root) ganglion and remains dormant until reactivation occurs (as shown in Figure 2.4.7) 
(49).   
 
 
Figure 2.5.7 Natural history of Herpes simplex virus (HSV) infection (49) 
 
Clinical features can vary depending on the affected area. General features include (49):  
 Typical lesions start as vesicles (Figure 2.4.8) and then become superficial painful 
ulcers. The ulcers can then form larger superficial lesions with characteristic 
serpiginous edges. 
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 Local tender lymphadenopathy 
 Muscle aches in the lower limbs 
 Systemic symptoms such as headache, malaise, and photophobia are present in 10% 
of patients 
 In women, other features such as fissures, erythema and dysuria might be present. 
Dysuria, due to urethral HSV infection, can be wrongly diagnosed as urinary tract infection if 
patients  are not examined properly (49).  
Recurrent episodes are common in HSV infection and are caused by the reactivation of the 
virus from the dorsal root ganglion of the sensory nerve (49). Pre-disposing factors  include 
intercurrent infection, psychological stress, trauma and ultraviolet exposure on the area of the 
affected dermatome (49). The recurrent episodes can occur anywhere on the dermatome and 
usually settle into a pattern (49). 
 
Figure 2.5.8 Herpetic vesicles 
(Source: http://www.ultramag50.com/category/natural-herpes-cure/page/694/) 
 
 Mycoplasma genitalium  
Mycoplasma genitalium was initially isolated in 1980 (54). The infection is strongly associated 
with male non-gonococcal urethritis and even more strongly with non-chlamydial non-
gonococcal urethritis (NCNGU). In men, Mycoplasma genitalium accounts for 10%-30% of 
NCNGU, although in the general population the prevalence ranges from 1% to 3.3% (54). In 
women, some studies indicated an association between M. genitalium  and cervicitis (pooled 
odds ratio (OR) 1.66), PID (pooled OR 2.14), tubal infertility (pooled OR 2.43) and urethritis 
(55).  
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Transmission of M. genitalium is primarily by genital-genital mucosal contact, although 
transmission from penile-anal sexual contact has also been found. Oral-genital transmission is 
less likely given the low number of M. genitalium in the oro-pharynx.  
Clinical features in women (urogenital infection) include (45, 47): 
 Cervicitis 
 40-75%% are asymptomatic among presentations at sexually transmitted diseases 
(STD) clinics. 
 Vaginal discharge (<50%)  
 Dysuria and/or urgency (30%) 
 Lower abdominal pain (<20%) (might increase suspicion of PID). 
 
2.5.2.1.5 Genital tract neoplasia 
Neoplasia can also cause vaginal discharge. One of the most common neoplasias in women 
with immunosuppression is cervical cancer, which is due to human papillomavirus infection 
(49). 
 
2.5.2.2 Pelvic Inflammatory Diseases 
Pelvic inflammatory disease (PID) (Figure 2.4.9) is a condition where there is an ascending 
infection from the vagina through the cervix into the upper genitalia tract and up to the 
abdominal cavity (49). Any young sexually active woman who complains of lower abdominal 
pain should be assessed for possible PID (49). The pathogen that causes PID is usually 
transmitted sexually (e.g. chlamydia, gonorrhoea and M. genitalium); most of the time, 
however, no pathogen can be isolated from the abdomen (57).  
 
Many women with pelvic inflammatory disease remain asymptomatic and will present with 
symptoms of complications of tubal damage such as infertility or chronic pelvic pain (49). 
Symptoms include (49): 
 Bilateral lower abdominal pain 
 Abnormal vaginal discharge 
 Intermenstrual and post-coital bleeding 
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 Dyspareunia.  
Signs include (49): 
 Bilateral lower abdominal tenderness 
 Adnexal tenderness on vaginal examination 
 Cervical motion tenderness on bimanual examination 
 Fever. 
  
 
Figure 2.5.9 Pelvic inflammatory disease diagram 
(Source: https://www.rchsd.org/health-articles/pelvic-inflammatory-disease-pid/) 
 
Diagnosis of PID is as follows (58) : 
 Rule out other differential diagnosis, especially ectopic pregnancy 
 Microscopy, culture or NAAT test for the causal microbes (Chlamydia trachomatis, 
Neisseria gonorrhoeae, and M. Genitalium) 
 Measure white blood count  
 Transvaginal ultrasound to detect fluid accumulation in the pelvic area, but unreliable 
for identifying uncomplicated tubal inflammation 
 Endometrial biopsy is easy to perform and can detect histological endometriosis, 
which is strongly related to upper genital tract inflammation; however, the risk of 
introducing infection while taking the biopsy and the time for the histological result to 
come back make this procedure less popular. 
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2.5.2.3 Ulceration  
Genital ulcer is a symptom and sign that may indicate acquisition of an STI. Herpes simplex 
virus (HSV), syphilis, chancroid, LGV and donovanosis are the most common sexually 
transmitted causes of genital ulceration. However, a genital ulcer can also appear as a symptom 
of a dermatological condition or trauma. The literature usually categorises genital ulcers based 
on the pain experienced by the patient (painful or painless), the number of ulcers (solitary or 
multiple), and the appearance of the ulcer’s edge and base.  Figure 2.4.10 shows genital ulcer 
stratification based on number of ulcers and pain characteristics.  
 
Figure 2.5.10 Causes of genital ulceration and erosions. Courtesy of Dr. F. Cowan (49) 
 
The two most common types of sexually-acquired ulceration (Herpes simplex and syphilis) 
and three rare causes of genital ulceration (LGV, chancroid and donovanosis) are discussed 
below.  
2.5.2.3.1 Herpes simplex virus 
See discussion above. 
 
2.5.2.3.2 Syphilis 
Syphilis is caused by a pathogenic organism called Treponema pallidum, from the 
spirochaetaceae family, genus treponema.  With an incubation period of 9-90 days, syphilis 
infection is divided into primary, secondary and latent phases; the latter is categorised into 
early syphilis and tertiary syphilis (called late syphilis) (49). The primary stage of syphilis starts 
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with the first lesions, which are usually found at the inoculation sites; they begin as red macules, 
develop into papule and finally become ulcerated (49). These highly contagious but painless 
ulcers usually appear on genital or extra-genital areas such as lips, tongue and tonsils. Those 
that develop on the perianal region are very often undetected (49). Without treatment, these 
ulcers (called chancres) usually heal in 3-6 weeks (40, 50).   
 
The second stage of syphilis infection, secondary syphilis, starts 4-8 weeks after the first lesion 
appears (49). Lesions in this stage are usually generalised, and can affect the skin as well as 
mucus (49). The skin lesion can appear as macular or papular, papulosquamous, pustular, or 
erosion, and may mimic other diseases such as condylomata – hence this infection is known as 
“the great imitator” (60). In 50-60% of cases, generalised lymphadenopathy occurs, sometimes 
accompanied by fever and malaise (49,60). Other signs and symptoms of systemic conditions 
like hepatitis, glomerulonephritis, irido and choroidoretinitis and alopecia occur only rarely (< 
10%) (49).  
 
Untreated syphilis without signs and symptoms is called latent syphilis (49). Based on the 
duration of infection, it is divided into early stage (less than 2 years) and late stage (more than 
2 years) (40, 51). If the infection remains untreated, it can progress to a third stage involving 
more severe and life-threatening conditions such as neurosyphilis, meningovascular, 
parenchyma and gummatous syphilis (60).  
 
2.5.2.3.3 Lymphogranuloma venereum (LGV) 
Lymphogranuloma venereum (LGV), also known as climatic/tropical bubo or 
lymphogranuloma inguinale, is an infection caused by the C. trachomatis serovars L1, L2 and 
L3 (49). These serovars cause infections with marked lymphatic involvement whilst the other 
serovars (A-K) cause predominantly mucosal lesions (49). There are three stages in the clinical 
manifestation of LGV. 
 
Primary stage/transient genital ulceration (3-30 days after infection): 
 Transient papular or ulcerative lesion at the site of inoculation  
 Single, non-indurated and occasionally painful ulcer 
 Heals rapidly without scars. 
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Secondary stage/inguinal or anorectal syndrome (2-6 weeks after infection): 
 Inguinal/femoral lymphadenopathy and formation of buboes (enlarged, tender, painful 
glands in the groin), which are unilateral in two-thirds of cases (Figure 2.4.11) 
 ‘Groove sign’ – groove-like depression (enlargement of inguinal and femoral lymph 
node separated by inguinal ligament)   
 Inguinal buboes can suppurate and rupture. Inguinal buboes are more frequently seen 
in men than women because the areas of the cervix, posterior urethra, rectum and 
vagina drain into the deep iliac or perirectal lymph nodes. 
Tertiary stage/genital anorectal syndrome (can appear any number of years after untreated 
infection):  
 Lymphoedema caused by fibrosis and blockage of the lymphatic system. 
 Oedema of the vulva/penis (elephantiasis)  
 Oedema of the genitals might lead to deformity of the penis, or polypoid growths, 
fistulae, ulceration, and scarring (esthiomene) on the vulva. 
 
 
Figure 2.5.11 Inguinal bubo caused by LGV  
(Source:  http://hubpages.com/health/Lymphogranuloma-Venereum-Health-Relevance-
Clinical-Presentations-Diagnosis-And-Treatment. 
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2.5.2.3.4 Anorectal proctitis  
Anorectal infection with LGV is more common among MSM and couples who perform anal 
sex. The clinical symptoms of proctitis are: 
 Mucopurulent anal discharge 
 Anorectal bleeding 
 Constipation 
 A sensation of rectal fullness or incomplete defaecation 
 Tenesmus. 
The LGV biovar can be diagnosed with further genotyping, but not all laboratories can perform 
this test.  
 
2.5.2.3.5 Chancroid 
Chancroid (Figure 2.4.12) is a genital ulcer type of STI caused by Haemophilus ducreyi, a 
fastidious Gram-negative bacterium (49). Chancroid is characterised by a painful ulcer around 
the genital area which might persist for several weeks in the absence of treatment (49,61). 
Before the widespread introduction of syndromic management in the 1990s, H. ducreyi was 
the major cause of genital ulcer disease (62). The infection starts as a papule which progresses 
into a pustule and, finally, an ulcer (49,61). This infection can cause inguinal buboes in some 
cases. Haemophilus ducreyi infection has recently emerged as a cause of chronic limb 
ulceration in children and adults in the Pacific and Africa (62). 
 
 
Figure 2.5.12 Chancroid  
(Source: http://www.medthical.com/chancroid.html) 
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2.5.2.3.6 Donovanosis  
Donovanosis is a rare STI that is mainly seen in a sporadic pattern in Papua New Guinea (PNG), 
South Africa, Australia, India and Brazil (63). It has been known under several names, 
including granuloma inguinale and granuloma venerum. Donovanosis is caused by the 
organism Calymatobacterium granulomatis, although experts continue to argue for its 
reclassification as Klebsiella granulomatis comb nov because of the phylogenic similarity with 
Klebsiella sp. The incubation period is 50 days, with papules developing into 4 types of genital 
ulcer (granulomatous, hypertrophic, necrotic and sclerotic) (63). The genital area is affected in 
most cases (90%), with inguinal involvement in 10% of cases. The ulcers tend to grow more 
rapidly during pregnancy.  
 
2.5.2.4 Genital warts and cervical cancer 
2.5.2.4.1 Genital warts 
Genital warts (Figure 2.4.13) are the most common viral STI in most developed and 
developing countries (49). Genital warts are caused by human papillomavirus (HPV), a DNA 
virus that can cause infection in the cutaneous and mucosal epithelium (64). Currently more 
than 200 types of HPV have been identified, with more than 40 types capable of infecting the 
genital area. Visible genital warts are usually caused by HPV genotypes 6 and 11 (48,49).  
 
Clinical features include visible lumps (multiple or solitary) in the genital area, particularly 
around areas which become traumatised during sexual intercourse (40). The appearance of 
genital warts vary, as follows (49,65): 
 Condyloma acuminata (cauliflower-like appearance, pink or skin-coloured or 
hyperpigmented, usually non-keratinised on the mucosa). 
 Smooth papules (dome shape and skin coloured) 
 Flat papules (macular or slightly raised, flesh coloured with smooth surface, usually 
in cervix) 
 Keratotic warts (thick horny layer that can resemble common warts or seborrheic 
dermatitis).  
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Figure 2.5.13 Genital warts 
(Source:http://diseaseslab.com/genital-warts-men-women-pictures-symptoms-
causes-treatment/) 
 
2.5.2.4.2 Cervical Cancer 
This type of cancer is very important in the field of sexual health because it is due to infection 
with certain HPV genotypes (49). There are approximately 200 HPV genotypes that can be 
divided into low- and high-risk HPV groups reflecting their potential to induce cancer (49,64). 
The low-risk HPV group cannot cause cancer but can induce skin warts, as described above; 
90 % of genital warts are caused by this low-risk group, especially HPV type 6 and 11 (49,64). 
The high-risk HPV group, which can cause cancer, includes more than 10 types of virus (49). 
HPV genotypes 16 and 18 are responsible for 70% of cervical cancer; the other types are 31, 
35, 39, 45, 51, 52, 56 and 58 (64,66). Not all individuals infected with high-risk HPV 
genotypes will develop cervical cancer. Usually, HPV infections resolve spontaneously in 1-
2 years and therefore do not cause cancer. However, persistent infection with the high-risk 
HPV can lead to histological deformation and may generate cancer (64). 
 
Among patients diagnosed with cervical cancer (Figure 2.4.14), 80% arise from preexisting 
squamous dysplasia, and 20% are due to adenocarcinoma of the cervix (66). Cervical cancer 
patients are usually asymptomatic in the early stages but can present with intermenstrual or 
postcoital bleeding, dyspareunia or cervico-vaginal discharge (67). 
 
  
36 
 
 
Figure 2.5.14 Cancer of cervix  
(Source:http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/CervicalDi
sease/cervical_disease_and_neoplasia.htm 
 
 
2.6 Diagnosis  
 
There are a set of tests for screening blood, diagnosing infection and monitoring disease 
progression in an individual infected with HIV (68). These tests can be classified into those 
that detect antibody, identify antigen(s), detect or monitor viral nucleic acids, and provide an 
estimate of the T-lymphocyte count per unit volume (68).  
 
The routine procedure for detecting HIV infection varies between countries. The most common 
tests can be classified as screening assays and confirmatory or supplemental assays. The 
screening assay is designed to detect all infected individuals (18). These tests have a high 
degree of sensitivity and yield few false negative results. Compared to screening assays, the 
confirmatory tests are designed to detect individuals who are not infected in the presence of a 
reactive screening test outcome. These tests possess a high degree of specificity and produce 
very few false positive results. Both tests, if performed in sequence, can produce a high level 
of accuracy and reliability. However, it is important to consider that errors do occur and that 
biological factors might affect the accuracy of the test. 
2.6.1.1 Early detection and window period 
The human body can produce antibodies against HIV shortly after infection, but this also 
depends on the characteristics of the virus and host. The latest 4th generation assays, which can 
detect HIV Ab and p24 antigen, give fewer false positives and false negatives than the previous 
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3rd generation assay and can detect the antibody at about 3-4 weeks after infection – a marked 
improvement over the earlier assays which could only detect antibody at around 6-12 weeks. 
These time ranges are called window periods (68,69). Almost all the assays on the market today 
are reliable and have an extremely high degree of sensitivity, but they vary in their ability to 
detect a low level of antibody in those who not yet fully seroconverted (68). 
2.6.1.2 Serological screening tests 
Several types of screening tests are available - enzyme-linked immunosorbent assay (ELISA), 
rapid tests, and so-called simple tests (68).  
2.6.1.2.1 Enzyme-linked immunosorbent assay (ELISA)   
ELISA is the most commonly used HIV screening test in the world. It is relatively simple, 
exhibits high sensitivity and is suitable for testing large samples (68). The test is based on 
detecting the HIV antibody in the sample using the antigen-antibody-human anti-human 
immunoglobulin with a bound enzyme method and then reading with a spectrophotometer (68). 
The antigen is provided in the test well on the ELISA test kit, and anti-human immunoglobulin 
is then added as a conjugate. Over 40 brands of ELISA test kit are available worldwide (18).  
 
The latest 4th generation combination of ELISA assay can shorten the window period of HIV 
to about 2 weeks. This method combines antibody detection with p24 antigen detection, which 
can increase the sensitivity of the test even in a low antibody condition and reduce the window 
period (68). This combination can be even more effective in the early infection test if combined 
with a viral RNA test. However, the viral RNA test is expensive, time-consuming and not 
available in all laboratories, especially in some developing countries (68).  
2.6.1.2.2 Rapid HIV test  
The rapid test is used to screen individuals for HIV in less than 30 minutes. It is usually used 
in specific time-sensitive situations such as in an emergency room, during the labor of a mother 
whose HIV status is unknown (because she was not screened during antenatal care), needle 
stick injury, and physician’s private practice testing (68). This method is similar to ELISA in 
that it specifically detects HIV antibody (70). If the rapid test is performed seamlessly, this 
method can be as accurate as the ELISA test (71). It is easy to perform and can be used in less 
developed countries where facilities, electricity supply and formal education of laboratory staff 
are less than optimal (68). The control strip in the rapid test is important to ensure that the 
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reagent is added correctly and the procedure is performed appropriately. Disadvantages of this 
test include subjective interpretation, difficulty in reading if the reader is colour-blind, and 
higher cost than ELISA (18). There are several types of rapid test (68): 
 Dot blot or immunoblot with 2 strips of control and test result which usually cannot 
differentiate between HIV-1 and HIV-2 
 2 dots type which can differentiate between the two types of HIV 
 The newer 1 step assays (immunochromatographic assays) are more convenient and 
self-contained. Usually, no reagent needs to be added because it is already impregnated 
in the flat cartridge device (68,70). 
 Some of the newer rapid tests can even differentiate the type of the virus. 
2.6.1.3 Confirmatory testing  
2.6.1.3.1 Western blot  
Most authorities around the world consider western blot as a gold standard confirmatory HIV 
test (18). The method uses an electrophoretic technique to separate HIV antigens from the virus 
(68). The HIV-1 viral antigens are separated as follows (from top to bottom): gp160, gp120, 
p66, p55, p51, gp41, p31, p24, p17, and p15 (Figure 2.5.1). The "gp" designation refers to 
glycoproteins; "p" indicates proteins. The numeric values (x100) indicate molecular weights. 
It is important to remember that non-viral proteins derived from the host cells in which the 
virus was grown are also present on the nitrocellulose strip. They can form bands in many 
places but are often near the middle molecular weight (40,000 to 60,000) region. These non-
viral protein bands may render an interpretation of results difficult by producing non-specific 
reactions.  For the HIV-2 tests, the WHO requires reactivity to at least 2 HIV-2 envelope 
antigens, whereas other organisations require reactivity to p26 (Gag) and gp34 or gp105 (Env). 
If a specimen is tested by both HIV-1 and HIV-2 Western blot, the blot exhibiting the strongest 
reactivity to envelope antigens usually indicates which infection is present.” (68) 
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Figure 2.6.1 Examples of reactions with an HIV-1 western blot 
 
After the viral components denature, the antigens are imparted with a negative charge. They 
are then separated based on their molecular weights, enabling the antibody reacting with each 
viral antigen to be identified (68). Disadvantages of this method include its non-quantitative 
nature and the need for a trained laboratory technician to perform the test (18). Moreover, some 
conditions might produce indeterminate results on western blot, such as nonspecific reactions, 
hypergammaglobulinemia, and infection by another retrovirus (18,68). False positive results 
can also occur in autoimmune patients, such as those with systemic lupus erythematosus 
(18,68). 
2.6.1.3.2 Direct immunofluorescent antibody assay 
This technique utilises the antibody-antigen reaction. Antigen derived from infected 
lymphocytes reacts with specific HIV antibodies which have a fluorescence label. Result 
visualisation is performed using a fluorescent microscope. This method is usually used to test 
sera producing indeterminate western blot test results (68). Unlike the direct method, which 
uses only one antibody, this method uses 2 antibodies - unconjugated primary antibody and a 
fluorophore-conjugated secondary antibody directed against the primary antibody. 
2.6.1.3.3 Modified western blot 
This technique can identify and differentiate between HIV-1 and HIV-2 virus infection (68). 
In this case, multiple HIV-1 antigens and one HIV-2-specific band (gp36 or gp41) are present 
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on the strip. Criteria established by manufacturers include reactions to one gene product from 
each of the 3 major groups (Gag, Pol, and Env) for positivity for HIV-1. To be considered 
positive for HIV-2, the test must show reactions to the HIV-2-specific antigen plus a reaction 
to HIV-1-specific antigens, which alone do not meet the criteria for positivity for HIV-1 (68).  
2.6.1.3.4 Line immunoassay  
This test is an alternative to the classic western blot. The difference is that this technique 
involves the application of recombinant or synthetic peptide antigens to a nitrocellulose strip, 
whereas electrophoresis is used in the western blot. This method is quite popular in Europe 
(71). 
2.6.1.4 Non-serological tests for HIV infection: Nucleic acid amplification tests 
(NAATs) 
In vitro nucleic acid amplification tests (NAAT) have broadened the range of microbiology 
detection, identification and characterisation of pathogenic organisms (71). This technique has 
reduced or, in some cases, even replaced the use of culture-based testing and microscopy 
examination to detect STI pathogens, especially for unculturable pathogens. NAATs involve 
so-called target amplification systems, which are defined as NAAT procedures that make as 
many copies as possible of the nucleic acid of the target object (72). These systems include 
Polymerase Chain Reaction (PCR), Transcription-Mediated Amplification (TMA), Nucleic 
Acid Sequence-Based Amplification (NASBA), and Strand Displacement Amplification 
(SDA) (71). Of these, PCR and its derived techniques, for which the original license and patent 
are held by Roche, are probably the most commonly used forms of the assay (71). 
 
PCR needs four materials - the DNA of the organism, primer of the target DNA, Taq 
polymerase enzyme (heat resistant) and nucleotides. All the materials are placed into one PCR 
tube. PCR consists of 3 processes -  denaturation, annealing and extension (73). Denaturation 
is the process of separating the double stranded DNA into single strands (71). In a PCR machine 
or thermal cycler machine, denaturation takes place when the temperature reaches around 95o 
C; the double stranded DNA then becomes single-stranded DNA (71). The temperature in the 
machine is then reduced to 55o-65o C, at which point the annealing process begins. At this 
stage, the primer binds to the complement nucleotide sequence within the single stranded DNA 
(71). The extension process begins as the temperature reaches 72o C (71). In the extension 
stage, the Taq polymerase enzymes start to attach the free nucleotides to their complementary 
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bases on the single stranded DNA (71). The extension starts from where the primers attach.  
After the taq polymerase enzyme reaches the end of the single stranded DNA, the first cycle is 
completed and the copies of double stranded DNA are created (71). This cycle is repeated 
around 30 times to copy as much DNA of the target organism as possible. After 30 cycles, 
more than 1 million copies of DNA will be available in the test tube (71).  
 
The PCR requires a double stranded DNA template to initiate the process. For HIV detection, 
which involves RNA virus, the process is called Reverse Transcription PCR. This technique 
transcribes RNA of the virus into a complementary (c) double stranded DNA using reverse 
transcriptase enzymes. After the complementary DNA becomes available, the process of PCR 
can be started (71). 
 
2.6.1.5 Other considerations  
HIV testing is an important part of HIV management. If an appropriate diagnostic test is not 
conducted, it is not possible to confirm the diagnosis, which might cause loss of cases and 
further transmission of HIV (46). There are several considerations for HIV testing, including:  
 PCR or other nucleic acid amplification test for HIV in the newborn babies. Maternal 
antibodies of the seroconverted mother can be detected in serological tests, leading to 
a false positive result for the baby. NAAT test should be the first option to test for HIV 
in newborn babies. 
 False negative result for HIV-1 group O. There has been a case of false negative results 
for HIV-1 group O that resulted in failure to detect the virus. PCR (or another NAAT) 
can, however, be used to detect false negative HIV-1 group O. 
 Minimally reactive western blot result in an early infected (seroconverting) individual. 
In newly infected (seroconverting) patients, the reactive western blot can be minimal, 
and this confirmatory test sometimes needs to be repeated to get a better result. 
 Technical errors.  
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2.6.2.1 Syndromic approach 
Aetiological diagnosis and clinical diagnosis are classical approaches to STI diagnosis. 
Aetiological diagnosis is reliant on laboratory tests to identify the causative agent, while 
clinical diagnosis relies on clinical experience to identify typical symptoms for a specific STI 
(74). However, only a few developing countries have health centres with the laboratory 
equipment and skills required for the aetiological diagnosis of STIs. In response, the syndromic 
approach was introduced in the late 1990s (57). WHO developed a simplified tool comprising 
flowcharts and algorithms to guide health workers in syndromic management implementation 
(74). 
 
Although this syndromic approach is straightforward and easy to perform, it requires some 
training in how to explore the chief complaint and symptoms and take a history (74). The chief 
complaint is really important as it is what brings patients to clinics. The chief complaint will 
direct the health practitioner to the suitable algorithm (74).   
 
Several chief complaints are important in the syndromic approach. Those discussed below are 
vaginal discharge, genital ulcer, lower abdominal pain and inguinal swelling syndromes (see 
Table 2.5.1 and Figures 2.5.2-2.5.5).  
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Table 2.6.1  
Syndromic Approach Symptoms, Signs and Causative Agents (74) 
Syndrome Symptoms Signs Most common 
causes 
Vaginal 
discharge 
Unusual vaginal 
discharge 
Vaginal itching 
Dysuria (pain on 
urination) 
Dyspareunia (pain 
during sexual 
intercourse) 
Abnormal vaginal 
discharge 
Bacterial vaginosis 
Vaginitis : 
- Trichomoniasis 
- Candidiasis 
Cervicitis :  
- Gonorrhoea 
- Chlamydia  
- Mycoplasma 
genitalium  
Urethral 
discharge 
Urethral discharge  
Dysuria 
Frequent urination 
Urethral discharge (if 
necessary ask patient to 
milk urethra) 
Gonorrhoea  
Chlamydia  
Mycoplasma 
genitalium  
Genital ulcer Genital sore Genital ulcer Genital herpes 
Syphilis  
Chancroid 
LGV 
Donovanosis  
Lower 
abdominal pain 
Lower abdominal 
pain 
Dyspareunia  
Vaginal discharge 
Lower abdominal 
Tenderness on palpation  
Temperature >38o 
Gonorrhoea  
Chlamydia  
Mixed anaerobes  
Scrotal swelling  Scrotal pain and 
swelling 
Scrotal swelling  Gonorrhoea 
Chlamydia  
Inguinal bubo Painful enlarged 
inguinal lymph 
nodes 
Enlarged inguinal lymph 
nodes 
Fluctuation  
Abcess or fistulae 
LGV  
Chancroid  
Neonatal 
conjunctivitis  
Swollen eyelids 
Discharge 
Baby cannot open 
eyes 
Oedema of the eyelids 
Purulent discharge  
Gonorrhoea  
Chlamydia  
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2.6.2.1.1 Vaginal discharge  
Vaginal discharge is a common STI symptom seen in patients presenting to clinics, although 
not all discharges are caused by infection. Foreign objects (e.g. tampons, retained condoms) 
and some physiological conditions can also cause vaginal discharge (Figure 2.5.2) (49). 
 
 
 
Figure 2.6.2 Vaginal discharge diagnosis algorithm (74) 
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2.6.2.1.2 Genital ulcer  
Genital ulcer (figure 2.5.3) is one of STI symptoms, usually caused by herpes simplex, 
syphilis, LGV, chancroid and donovanosis. It can vary from painless to sore ulcer and single 
to solitary ulcer. 
 
 
Figure 2.6.3 Genital ulcer diagnosis algorithm (74) 
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2.6.2.1.3 Lower abdominal pain  
Lower abdominal pain (figure 2.5.4) is usually experienced by women; the symptom is 
caused by inflammation of the abdominal cavity in the lower region. 
 
Figure 2.6.4 Lower abdominal pain diagnosis algorithm (74) 
  
  
47 
 
 
2.6.2.1.4 Inguinal swelling  
Inguinal swelling (figure 2.5.5) can be caused by various conditions. Therefore specific 
interview to explore the possible caused is necessary. The present of an ulcer on the swelling 
also a good indication of Inguinal swelling caused by STI.  
 
Figure 2.6.5 Inguinal swelling diagnosis algorithm (74) 
 
  
2.6.2.2 Aetiological tests 
2.6.2.2.1 Based on the test method 
Based on the type of the test there are several tests available to diagnose the causative agent(s) 
of STI.  
 Microscopy  
The principle of microscopy examination involves magnification of a fixed and stained 
specimen to detect the presence or absence of a pathogen (72). The light microscope utilises 
light sources from under the object glass, and the object glass is then observed through 
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combined magnifying lenses (72). Histochemical staining is used to help the observer 
identify certain cells, cell structures and microbes. Basic specimen preparation (72) 
involves fixation of the specimen with formalin or epoxy resin (for nonliving specimens) 
or gentle heating above the Bunsen flame (for living specimens). There are several types 
of staining processes; selection depends on the type of test and the microbe that might be 
expected in the specimen (Table 2.5.2) (72) 
 
 
 
Table 2.6.2 
Examples of Histochemical Stains and their Uses  
 
 
 
 Enzyme-linked immunosorbent assay (ELISA) 
The test principle of ELISA was described earlier under HIV screening.  
 Serological test  
This test is principally used to detect the presence of specific IgM or to measure the 
increasing titer of the antibody that is produced by the immune system as a normal reaction 
of the body to counter the specific antigen of the microbe (72). The measurement of the 
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antibody is usually performed twice, once in the acute phase (acute serum) and again 10-
14 days after the onset of symptoms (72). A four-fold or greater increase in the antibody 
titer between the first and second measurements is considered to indicate the onset of acute 
infection (75). 
 Nucleic Acid Amplification Tests (NAATs) 
The test principle was explained above under HIV alternative test.  
 Culture  
The basic principle of culture is to create suitable environmental conditions for a specific 
microbe to grow and replicate. The following requirements apply (72): 
 precisely controlled procedure relying on chemically defined media or defined cell 
lines (http://www.lgcstandards-atcc.org/) 
 a sterile and suitable growth medium containing nutrient (Table 2.5.3) 
 suitable or optimised conditions of pH, temperature, humidity, pressure, ionic and 
osmotic pressure. 
 appropriate handling (aseptic technique) to avoid contamination. 
 
Table 2.6.3 
Culture Media and Types of Organisms Isolated (76) 
 
 
2.6.2.2.2 Based on the causative agent  
 Neisseria gonorrhoeae 
There are 3 main methods for diagnosing Neisseria gonorrhoeae.  
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Culture  
Neisseria gonorrhoeae can be cultured using a modified Thayer Martin medium. 
Characteristics of the culture (49):  
 High specificity ( ∼ 100%) in all sites  
 Medium sensitivity (80– 90%) in genital sites  
 Isolate available for antimicrobial susceptibility testing  
 Transport/storage critical  
 Labour intensive  
 Requires invasive specimens (urethral/cervical swabs) 
Microscopic test  
Neisseria gonorrhoeae may be detected using microscopic Gram stain for bacteria. The Gram 
negative N. gonorrhoeae will be visible as pink on the object glass because the bacteria retain 
the counterstain (e.g. safranin) whilst Gram positive will appear blue as they retain the crystal 
violet (72). The method is as follows (72):  
A heat-fixed smear of bacterial cells is flooded with crystal violet for 30 seconds before a quick 
rinse with water. It is then flooded with Gram’s iodine for 60 seconds before being rinsed with 
water. Next, it is decolourised with 95% (v/v) ethanol then water-rinsed again. The specimen 
is then counterstained, for example with safranin, for 60 seconds, before being rinsed with 
water and carefully blotted dry before examination with the aid of a light microscope using an 
oil immersion lens.  
Characteristics of STI tests using microscopy (49):  
 Rapid: performed while patient waits in clinic  
 Sensitive in symptomatic males (95%)  
 Lacks sensitivity in women, asymptomatic males and extragenital samples. 
 
Nucleic acid amplification test (NAAT) e.g. PCR  
In the past, culture isolation of N. gonorrhoeae was the gold standard for diagnosis of 
gonorrhoeae, but nucleic acid amplification tests (NAATs) provide a faster and more cost-
effective method (49). Microscopic Gram staining procedure is the least sensitive and specific 
among these methods but is the cheapest and fastest method and is still used by many 
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developing countries (49). The technology of NAAT is easily automated and combined with 
the detection of C. trachomatis. A positive predictive value of >90% is desirable when using 
this method in high prevalence populations (49).  On extragenital samples, contamination with 
other microbes in the ano-rectum and another type of Neisseria species on the oro-pharynx 
makes it even harder to diagnose N. gonorrhoeae using culture. NAATs are known to be 
superior at these sites and give more positive results than culture (49). Characteristics of 
NAATs (49):  
 Automated and rapid  
 High sensitivity (90– 100%)  
 Suitable for non-invasive specimens (self-taken vaginal swabs and urine) 
 Some commercial platforms lack specificity, so false positive results can occur  
 Implementing confirmatory testing (employing a second molecular test with a 
different target site) reduces the chance of false positive results. 
 
 Chlamydia trachomatis and LGV  
There are 4 methods of diagnosing chlamydia: 
Culture  
The culture of chlamydia utilises tissue cultured cells (e.g. McCoy cells) followed by 
microscopic examination (49,76). Characteristics include (49):  
 High specificity ( ∼ 100%)  
 Low sensitivity ( ∼ 65– 75%)  
 Requires invasive specimens (urethral/cervical swabs)  
 Transport/storage critical  
 Technically complex  
Direct immunofluorescence  
This type of test utilises fluorescence-labeled antibodies and microscopic examination to 
visualise inclusion bodies (49). Characteristics:  
 High specificity ( ∼ 99%) with experienced personnel  
 Rapid: ∼ 2 hour turnaround time  
 Low sensitivity (70– 80%)  
 Labour intensive and non-automatable. 
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ELISA 
A human antibody that attaches to chlamydial lipopolysaccharide (LPS) as the antigen is 
detected using this method (49). Characteristics (49):   
 Intermediate sensitivity (∼ 60– 70%)  
 High specificity in genital specimens ( ∼ 80– 90%)  
 Semi-automated: suitable for large-scale screening  
 Low specificity in extra-genital specimens 
NAATs  
This method is the gold standard for the diagnosis of chlamydia infection because of its high 
sensitivity and specificity (49). It is even recommended for the detection of  C. trachomatis on 
suspected low-level chlamydia specimens such as urine and self-taken vaginal swabs (77). 
Nowadays, chlamydia culture and enzyme immunoassay are rarely performed by health 
facilities. The chlamydia NAAT can be performed in combination with a gonorrhoea NAAT 
on the same platform, which might reduce the cost and be more efficient. Characteristics (49): 
 High sensitivity and specificity ( > 90% and > 90%)  
 Automated and rapid  
 Suitable for non-invasive specimens (vulvovaginal swabs and urine)  
 Specificity can be compromised by contamination 
 
 LGV 
Detection of LGV is similar to detection of C. trachomatis genotype D-K as the cause of 
chlamydial infection. Fluorescent staining of the rectal biopsy has previously been used to 
diagnose LGV on a suspected proctitis patient. Further genotyping to identify biovar LGV 
(genotypes L1-3) should be performed through fluorescent genotyping of the cultured LGV. 
 
 Treponema pallidum 
Nucleic acid amplification test (NAAT) 
Diagnostic methods using dark field microscopy to examine primary and secondary serum 
lesions could be used to detect the microorganism. Tests with higher sensitivity and specificity, 
such as NAAT, will, however, definitely catch the infection (49). Serological testing is also 
very good in terms of screening and confirmation of the diagnosis, but because of the 
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differences between these tests (TPPA, TPHA, RPR, VDRL) they are complementary (i.e. 
more than one test is needed to screen and to confirm) (49). This test was explained earlier. 
Dark ground microscopy  
This test can be used to detect the pathogen from the lesions of primary and secondary syphilis. 
Identification of the bluish-white, coiled shape of Treponema (figure 2.5.6) was once an 
important test for primary syphilis (72), but this test has now been replaced by others (49,78). 
The method is as follows (72):  
 The lesion is cleaned using sterile gauze and normal saline. 
 The gauze is used to squeeze the lesion a little to encourage some exudate. 
 The serum exudate from the lesion is scraped off and placed on a slide (the process is 
repeated three times).  
 The 3 slides are then checked under the microscope. 
 If there is a high index of suspicion of syphilis, dark ground microscopy examinations 
can be repeated daily for 3 consecutive days.  
 
 
Figure 2.6.6 Dark microscopy of T. pallidum  
(Source:https://microbewiki.kenyon.edu/index.php/The_History_and_Transmission_
of_Treponema_pallidum;_Syphilis) 
 
Treponemal serology  
There are 2 types of treponemal serological tests, non-specific and specific. 
Non-specific tests (assay for detecting active infection) are rapid plasma reagen (RPR) and 
venereal disease reference laboratory (VDRL). These tests are based on agglutination (RPR) 
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and flocculation (VDRL); both detect host cardiolipin antibody in the serum (18). The 
cardiolipin antibody usually becomes positive 3-5 weeks after the patient has contracted an 
infection (49). This test can be used to monitor stage and treatment response. However, the 
VDRL and RPR titers also decay naturally without treatment so that an untreated individual 
can have active disease with a low or negative titer (79). Characteristics (49):  
 Quantitative test 
 Active infection is assumed when serum is reactive at high titer (≥ 1:16), although 
active early disease can be present with lower or, in the case of some primary syphilis 
cases, negative non-specific treponemal tests 
 Cheap, reproducible, easy to perform  
 In some countries, RPR/VDRL are used as screening tests 
 False positive in pregnancy, old age, HIV infection or after acute infections (herpes, 
measles, mumps), after some immunisations (e.g. typhoid), and in chronic 
autoimmune diseases as well as rheumatoid arthritis. 
Specific tests 
 T. pallidum enzyme immunoassay (EIA)  
 T. pallidum particle agglutination assay (TPPA) 
 T. pallidum haemagglutination assay (TPHA) 
 FTA IgG (or total Ab) 
 FTA IgM specific 
EIA tests usually become positive in early infection, and EIAs based on combined IgG/IgM 
detection will become positive 2-4 weeks after infection. Some laboratories use non-
treponemal test first to screen suspected individuals then continue with a treponemal test to 
confirm the result (Figure 2.5.7)  Other laboratories use the ‘reverse algorithm’, that is, screen 
with a treponemal test first (usually EIA) and undertake RPR/VDRL testing in cases that are 
positive for treponemal antibodies. Characteristics (49): 
 High sensitivity and specificity (> 95%)  
 Cheap to perform  
 EIA tests can be automated and electronically reported  
 Reactive tests do not discriminate between past/recent infections  
 Tests can be insensitive if used in very early infection  
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 In low prevalence populations, the absence of confirmatory testing will result in a high 
number of false positive results. 
  
Figure 2.6.7 Algorithm for syphilis testing (79) 
 
 Haemophilus ducreyi 
Microscopy 
Haemophilus ducreyi has a unique tendency to form autoagglutination in liquid culture or a 
cohesive colonial structure on agar plates (62). There are various descriptions of H. ducreyi 
under microscopy examination, such as “school of fish”, “railroad tracks” and “fingerprints” 
(Figure 2.5.8) (62). Other characteristics of this organism include the fact that it is more often 
found extracellularly than intracellularly and has close proximity to polymorphonuclear (PMN) 
leukocytes (61). Overall, due to the misleading tendency of H. ducreyi with another 
microorganism on ulcer swab examination using gram stain and the superior ability of culture 
to detect this organism, microscopy is not recommended for diagnosis of H. ducreyi infection 
(49,62). 
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Figure 2.6.8 Microscopy appearance of H. ducreyi on gentian violet staining 
(Source: https://phil.cdc.gov/phil/details_linked.asp?pid=2119) 
 
Culture 
Most laboratories use culture to detect H. ducreyi as the cause of chancroid (49). It used to be 
the gold standard for comparing new methods of detecting H. ducreyi, but culture is rarely used 
today because the prevalence of chancroid has declined in those countries where it was once 
endemic. Conventionally, the culture of this organism is achieved using a specific agar plate 
containing vancomycin (3mg/L) to suppress the Gram-positive skin bacteria; the accuracy of 
the diagnosis can be increased by using more than one type of medium in the primary culture 
(62). The freshness of the media, maintaining incubation temperature at 33o-35o, and immediate 
bedside inoculation are necessary to successfully grow this fastidious bacteria (62). Due to 
technical difficulties in most settings and the cost of culture testing for this organism, more 
sensitive nucleic acid amplification tests are preferred for H. ducreyi detection (62).  
Culture media include (61): 
 GC agar supplemented with 1% haemoglobin, 5% fetal calf serum, 1% IsoVitaleX, 
and 3 mg/l vancomycin 
 Mueller‐Hinton agar supplemented with 5% chocolatised horse blood, 1% IsoVitaleX, 
and 3 mg/l vancomycin 
 GC agar supplemented with 1% haemoglobin, 0.2% activated charcoal, 1% 
IsoVitaleX, and 3 mg/l vancomycin.  
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Nucleic acid amplification tests (NAATs) 
NAATs are now the preferred method of detecting H. ducreyi in the laboratory due to their 
high sensitivity and specificity (49). Currently, there is no specific H. ducreyi test on the 
market. Most laboratories usually use a multiplex PCR test, which runs several different tests 
simultaneously (e.g. HSV, T. pallidum, H. ducreyi) (61).   
 
 Mycoplasma genitalium  
Mycoplasmas are the smallest organisms that can reproduce in cell-free bacteriological media 
(Figure 2.5.9) (73). 
 
Figure 2.6.9 Mycoplasma genitalium  
 
NAATs 
In clinical specimens, NAATs are the only useful diagnostic method. The primers to detect M. 
genitalium are available on the market, although some diagnostic centres simultaneously run 
the M. genitalium test as a multiplex assay with N. gonorrhoeae and C. trachomatis (54). Due 
to widespread resistance of M. genitalium to macrolides, all positive test results need to be 
followed up and any treatment failures should be screened for the 23S rRNA mutation 
associated with macrolide resistance in M. genitalium (54). 
 
 Donovanosis  
Direct microscopy 
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A rapid Giemsa stain can be used to stain the tissue of the ulcer. The tissue is characterised by 
large mononuclear cells with intra-cytoplasmic cysts filled with deeply stained Gram-negative 
Donovan bodies. 
Culture  
This method can only be performed in two places in the world and is not done routinely. 
NAATs 
A multiplex PCR test has been developed using an in-house NAAT involving C. Granulomatis 
primers. The number of laboratories that can perform this method is, however, very limited. 
 
2.7 Management of HIV-STI 
 
2.7.1.1 Treatment 
In general, the focus of HIV management is to reduce HIV replication in the body until the 
viral load is undetectable in order to prevent further deterioration of the immune system. The 
risk of immune reconstitution is high in patients whose immunity is low at the commencement 
of antiretroviral therapy (80). 
 
Highly active antiretroviral therapy (HAART), a combination of several antiretrovirals to 
suppress HIV growth, is the mainstay of modern HIV management. A gradual recovery of CD4 
T-cells and improvement of the immune response are the indicators of successful long-term 
HAART (80). The introduction of HAART in early 1990 led to a reduction in the annual 
mortality rate in 7000 men with HIV from 7% in 1996 to  1.3% in 2004 (81).  
 
Previously, HAART was initiated when the CD4 count was below 350 or even below 200 cells 
per cubic millimeter (mm3) in some settings with limited resources. Another study  (CIPRA 
HT 001) (n=816), however, which began in Haiti in 2005, showed that the earliest possible 
initiation of HAART (2 weeks after enrollment, on average), irrespective of any CD4 counts, 
gave superior results compared to initiation of HAART after CD4 counts fell below 200 mm3 
(7). Mortality was reduced fourfold for the early initiation group compared to the late initiation 
group in this CIPRA HT 001 trial (7). The CIPRA HT 001 study board then halted the trial and 
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offered the early initiation therapy to all participants (7). Another study (2011) which examined 
the survival rate of 661 HIV-infected patients with tuberculosis showed that participants who 
began HAART 2 weeks after the start of tuberculosis treatment (the early initiation group) 
reduced their mortality risk by nearly 38% (hazard ratio, 0.62, 95% CI; 0.44 to 0.86; p:0.006). 
The risk of reconstitution syndrome was increased significantly in the earlier-ART group 
(hazard ratio, 2.51; 95% CI, 1.78 to 3.59; P<0.001) (82). 
 
The latest WHO HIV treatment guidelines indicate that early initiation of HAART is regarded 
as best practice (83). ART should be initiated for every adult patient infected with HIV, 
regardless of the WHO clinical stage and CD4 count; the priority group are those HIV patients 
with advanced HIV clinical disease (WHO stage 3 or 4) and CD4 count ≤ 350 mm3 (83). For 
pregnant women, adolescents and children under 10 years, the guidelines recommend the 
initiation of HAART regardless of the clinical stage and CD4 count (83).  
HAART provides effective treatment options for treatment-naive and treatment-experienced 
patients. There are currently six classes of antiretroviral agents: 
 Nucleoside reverse transcriptase inhibitors (NRTIs) 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
 Protease inhibitors (PIs) 
 Integrase inhibitors (INSTIs) 
 Fusion inhibitors (FIs) 
 Chemokine receptor antagonists (CCR5 antagonists) 
 
First-line ART has traditionally consisted of 2 nucleoside reverse-transcriptase inhibitors 
(NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI). However, non-
nucleoside reverse-transcriptase inhibitors are now being replaced with integrase inhibitors as 
these are very potent and have fewer side effects (Table 2.6.1). 
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Table 2.7.1 
Recommended Regimen Options 
 
 
 
The yellow highlight: the evidence supporting this regimen is based on relative bioavailability 
data coupled with data from randomised, controlled switch trials demonstrating the safety and 
efficacy of TAF-containing regimen.  
 
The following combinations are available on the market:  
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 Stribild – elvitegravir (150 mg) + cobicistate (150 mg) + emtricitabine (200 mg) + 
tenofovir DF (300 mg) qd; this is a once-daily one pill regimen  
 Genvoya – elvitegravir (150 mg) + cobicistat (150 mg) + emtricitabine (200 mg) + 
tenofovir AFg (10 mg) qd; this is a once-daily one pill regimen  
 Odefsey – emtricitabine (200 mg) + rilpivirine (25 mg) + tenofovir AF (25 mg) qd; this 
is a once-daily  one pill regimen 
 Descovy – emtricitabine (200 mg) + tenofovir AF (25 mg) qd  
 Epzicom - Abacavir (600 mg) + lamivudine (300 mg) qd  
 Triumeq – Abacavir (300 mg) + dolutegravir (50 mg) + lamivudine (300 mg) qd  
 Trizivir - Abacavir (300 mg) + lamivudine (150 mg) + zidovudine (300 mg) bid  
 Truvada - Tenofovir DF (300 mg) + emtricitabine (200 mg) qd  
 Atripla - Tenofovir DF (300 mg) + emtricitabine (200 mg) + efavirenz (600 mg) qd  
 Complera – Tenofovir DF (300 mg) + emtricitabine (200 mg) + rilpivirine (25 mg) qd  
 Combivir - Zidovudine (300 mg) + lamivudine (150 mg) bid  
 Evotaz – Atazanavir (300 mg) + cobicistat (150 mg) qd  
 Prezcobix – Darunavir ethanolate (800 mg) + cobicistat (150 mg) qd  
 
*BID: two times a day, QD : once a day 
2.7.1.2 Monitoring  
Previously, the preferred way of monitoring HIV patients undergoing treatment was to monitor 
their clinical or immunological responses; in settings where viral load and CD4 tests are 
available, both can be performed (83). Given, however, that since 2013 WHO has 
recommended that treatment should start immediately, regardless of the CD4 count, it is more 
reasonable to focus on the viral load as a way of monitoring treatment adherence and resistance 
to ART among HIV patients (83). 
 
 
2.7.2.1 Treatment  
Treatment of STI can be through syndromic therapy or causative therapy. 
Table 2.6.2 summarises the syndromic management of STI treatment (syndromic and 
causative) 
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Table 2.7.2  
Syndromic and Causative  treatment of STI (Indonesian Guideline) (44) 
 * Cannot be given to pregnant or lactating women or children under 12 years. 
** No alcohol to be consumed. 
 
Syndrome Symptoms Signs Most common 
causes 
Treatment  Alternative  
Vaginal 
discharge 
 
 
Unusual vaginal discharge; Vaginal itching; 
Dysuria (pain on urination); Dyspareunia 
(pain during sexual intercourse) 
Abnormal vaginal discharge 
 
VAGINITIS:  
Trichomoniasis 
Candidiasis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERVICITIS:  
Gonorrhoea  
 
 
Metronidazole** 2 g per oral single 
dose 
 
(+) 
 
Miconazole OR Clotrymazole  200 
mg 
intravaginal, every  day, for 3 
days  
OR  
Clotrymazole  500 mg intravaginal 
single dose 
OR  
Fluconazole* 150 mg, per oral single 
dose  
OR  
Itraconazole* 200 mg, per oral single 
dose  
 
 
 
Ceftriaxone 250mg Intramuscular IM 
single dose 
 
Metronidazole** 2x300 mg/day per oral, 
For 7 days 
 (+) 
 
Nystatin, 100.000 IU, intravaginal every  
day for 7 days 
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Chlamydia 
Mycoplasma  
 
 
 
 
 
 
 
Or  
Cefixime 400 mg, single dose , per 
oral 
 
(+) 
 
Azithromycin 1 g, single dose, per 
oral 
Or  
Doxycycline* 2x100 mg/day, peroral, 
7 days 
Urethral 
discharge 
Dysuria (pain on urination), urethral 
discharge 
Urethral discharge Gonorrhoea  
 
 
 
 
Chlamydia 
Mycoplasma 
 
 
Ceftriaxone 250mg Intramuscular IM 
single dose 
Or  
Cefixime 400 mg, single dose , per 
oral 
 
(+) 
 
Azithromycin 1 g, single dose, per 
oral 
Or  
Doxycycline* 2x100 mg/day, per oral, 
7 days 
 
Genital ulcer  Genital sore Genital ulcer  Syphilis  
 
 
 
 
 
 
 
 
 
 
 
 
Benzathine benzylpenicillin 2.4 
Million IU, single dose IM 
 
 
 
 
(+) 
Penicillin-procaine IM 600.000 U/day for 
10 days 
or  
Doxycycline* 2x100 mg/day per oral, for 
30 days  
or 
Erythromycin 4x500 mg/day for 30 days 
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Chancroid  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genital herpes 
 
Ciprofloxacin*, 2x500 mg/day, per 
oral, for 3 days 
OR  
Erythromycin base, 4x500 mg/day, 
per oral, for 7 days 
OR  
Azithromycin 1 g, per oral, single 
dose  
 
(+) 
 
Aciclovir, 5x200 mg/day, per oral, for 
7 days 
OR  
Aciclovir 3x400 mg/day for 7 days 
OR  
Valaciclovir, 2x500 mg/day, per oral, 
for 7 days 
 
(+) 
 
Ceftriaxone 250 mg, IM, single dose 
 
Lower 
abdominal 
pain 
 
Lower abdominal pain Dyspareunia 
 
Vaginal discharge; Lower 
abdominal tenderness on 
palpation; Temperature >38° 
 
Gonorrhoea  
 
 
 
 
 
 
 
 
 
Chlamydia  
Mixed anaerobes 
Ceftriaxone 250mg Intramuscular IM 
single dose 
Or  
Cefixime 400 mg, single dose , per 
oral 
 
(+) 
 
Azithromycin 1 g, single dose, per 
oral 
Or  
Ceftriaxone 250 mg, injection IM, single 
dose  
 
 
 
(+) 
 
Erythromycin 4x500 mg/day, per oral, 7 
days 
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Doxycycline* 2x100 mg/day, per 
oral, 7 days  
 
 
 
 
 
Inguinal bubo  
 
Painful enlarged inguinal lymph nodes 
 
Enlarged inguinal lymph nodes; 
Fluctuation; Abscesses or 
fistulae 
 
LGV   
 
 
 
 
 
 
 
Chancroid 
Doxycycline * 2x100 mg/day, per 
oral, 14 -21 days 
 
(+)  
 
Ciprofloxacin* 2x500 mg/day per 
oral, for 3 days 
 
Or 
Azithromycin 1 g, single dose, per 
oral  
 
(+)  
 
Erythromycin 4x500 mg/day, per oral, 
for 14 days 
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2.8 HIV-STI Prevention in Indonesia 
 
2.8.1.1 Condoms  
Around the early 1990s, latex condoms were made available in Indonesia and their use 
was promoted by the government as a means of contraception (84). At that time, rates 
of HIV incidence and prevalence were relatively low (28). Awareness of an increasing 
prevalence of HIV was marked in 1995 by the establishment of the National AIDS 
Prevention Commission, whose mission was to help the government develop counter-
strategies (22). The campaign promoting condom is use as a means of HIV/STI 
prevention was initiated by the National AIDS Commission in collaboration with the 
Indonesian Ministry of Health. This campaign, however, only used health care 
providers as agents of change. Mass media and public figures, including high-ranking 
government officials, were reluctant to be seen to associate with an issue that attracted 
considerable controversy. There was concern that promoting condom usage might 
encourage promiscuity among adolescents and rejection by religious leaders who taught 
that condoms were evil (contraception is unacceptable in both Catholicism and Islam) 
(84). 
 
In the western part of Indonesia, the condom campaign kicked off on 1st December 
2006 - World AIDS Day - when Vice President Jusuf Kalla boldly instructed all 
ministers and provinces to support it in order to prevent further transmission of HIV. 
Through coordination with the family planning association, the government has begun 
to install condom ATMs around the designated areas and has distributed millions of 
condoms through primary health care facilities around the country. 
 
The provision of free condoms remains controversial for some groups in Indonesia 
today, even though research has demonstrated the effectiveness of the campaign in 
promoting safe sex behaviour. One meta-analysis, which examined 21 studies, 
concluded that the Indonesian condom campaign had “protective effects on sexual 
initiation among youth” (85). 
Papua, one of the provinces most impacted by the significant increase in HIV incidence, 
initiated the condom campaign in 2003. Some regulations were introduced by the local 
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government to support the campaign for 100% condom usage in the brothel area (which 
closed in 2015) (22).  The Provincial AIDS Commission has recorded 420 condom 
outlets in Papua today.  Between 2011 and 2014, a total of  1,811.678 condoms were 
distributed (22), with annual figures of 425,598,  747,360,  349,920 and 288,800 over 
that period.  
 
2.8.1.2 Sex education 
Four regulations of the National Ministry of Education are relevant to the provision of 
sex education in school  curricula (22): 
 No.22/2006 on the Content Standards for Basic and Secondary Education. 
 No.23/2006 on Graduates’ Competency Standards for Primary and Secondary 
Education. 
 No.70 /2013 on Basic Framework and Curriculum Structure of Vocational 
High School/Vocational Madrasah Aliyah. 
 No.14 /2007 on the Content Standards for P Programs A, B and C. 
There is only minimal reference to sex education in these regulations. The harmful 
effect of free sex is mentioned in Regulation no.3. STI  and  HIV prevention is referred 
to in all regulations. 
Implementation of these regulations is not explained in detail but is left up to local 
government, which is responsible for managing schools in all provinces. In some areas, 
where sex education is still considered morally unacceptable, the curriculum contains 
no sex education at all. In Papua, the sex education program is usually run by the school 
in collaboration with local primary health care services, the university, and the local 
AIDS Commission. Papuan local government regulation No.26/2010 seeks to 
mainstream education in HIV/AIDS; it provides technical guidelines, a basic syllabus, 
material mapping, integration of strategies and a self-development program. 
2.8.1.3 Behavioural change 
This strategy focuses on changing the behaviour of specific high-risk groups through 
extensive communication efforts, focus group discussion and mentoring. There are 
four  target groups (22): 
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 Primary: Sex workers, MSM, young people, wives of high-risk men (seafarers, 
moto-taxi drivers, drivers, dock workers), people with HIV. 
 Secondary: People who have direct contact with the primary target group and 
can potentially support or hinder behavioural change of primary target (family, 
support group). 
 Tertiary: Local community groups, institutions or individuals whose role 
enables them to promote or impede behavioural change (community leaders, 
NGOs, religious leaders). 
 Field workers: Officials who seek to promote change in a community. They 
normally belong to the community or to a change-oriented organisation. 
In Papua, the local AIDS Commission actively promotes behavioural change through 
local TV and radio via short advertisements that encourage HIV-STI awareness and 
condom use, emphasise the importance of HIV testing and provide information to 
reduce stigma and discrimination (22). 
 
 
2.8.2.1 Pre-exposure prophylaxis (PrEP) 
The latest WHO guidelines recommend oral PrEP containing TDF as an additional 
preventive strategy for people at high risk of acquiring HIV. In 2012, WHO 
recommended PrEP for serodiscordant couples, MSM and transgender people (86). In 
2014, through consolidated guidelines for high-risk populations, WHO strongly 
recommended PrEP for men who have sex with men. However, everyone who is at 
substantial risk of acquiring HIV should be offered PrEP (86). 
 
Several studies highlight the effectiveness of oral PrEP among serodiscordant couples, 
heterosexual men, women, men who have sex with men, injecting drug users and 
transgender women (86–91). With high adherence, significant levels of efficacy can be 
achieved (83). The regimen for PrEP is TDF or a combination of TDF and FTC 
(Truvada). PrEP can be discontinued 28 days after the last potential exposure to HIV-
infected fluid (86).  
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2.8.2.2 Post-exposure prophylaxis (PEP) 
This strategy is similar to PrEP in that it seeks to prevent the establishment of HIV 
infection (86). The difference is in the timing, as PrEP should be started before an 
anticipated sexual exposure occurs, whilst PEP is only started after exposure to 
suspected HIV-infected fluid (86). PEP is usually commenced after a needle stick injury 
or unexpected sexual activity with an individual suspected to be living with HIV (83). 
 
In Indonesia, PEP is widely available in the provincial hospitals. The use of PEP in 
MSM or people who inject drugs is rare because members of these groups avoid 
government institutions due to stigma and drug enforcement rules (22). The regimen 
and use of PEP are similar to those in PrEP, and either TDF or combination TDF and 
FTC is dispensed for 28 days. PEP must be commenced within 72 hours of the last 
potential contact with suspected HIV-infected body fluids. 
 
2.8.2.3 Periodic presumptive therapy (PPT) 
Presumptive therapy is “one-time treatment for a presumed infection in a person, or a 
group of people, at high risk of infection” (92). Periodic means that the treatment is 
given at repeated intervals. The regimen of PPT for gonorrhoea and chlamydia is as 
follows: 
 Azithromycin  1 gram, single oral dose 
 Plus  
 Doxycycline 100 mg twice a day orally for 7 days or Cefixime 400 mg, single 
dose oral (cefixime is used in Indonesia as a PPT). 
 
The recommendation from WHO is as follows (92):  
 Depending on the risk factor and conditions, PPT should be given once every 
1 to 3 months. 
 It should be given if the prevalence of chlamydia and gonorrhoea combined is 
more than 10% and condom use is below 70%. If this ideal condition is already 
achieved, then the health care provider can taper or end the PPT. 
 All new participants/sex workers who attend clinics for the first time should 
receive one round of PPT. 
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 If good, comprehensive, accessible and affordable services are available, and 
STI rates are declining, then the PPT can be tapered or terminated. 
 STI and condom use should be monitored, ideally every 2 years, depending on 
the resources.  
In Indonesia, the latest guidelines for PPT, released in July 2016 by the Ministry of 
Health, are similar to those of WHO, including the recommendation that it should be 
taken in front of a health officer (43). The Indonesian Health Ministry, however, made 
the following modifications:  
The PPT for FSW will be stopped if (42):  
 The rates of STI are less than 20%, gonorrhoea less than 10% and syphilis less 
than 1% 
 Consistent condom use has reached 60%. 
 
2.8.2.4 Circumcision 
Based on evidence from the Philippines and other parts of Indonesia where the 
incidence of HIV is lower, Papua province introduced circumcision in 2008 (22). In 
2015, a new method of circumcision was introduced following a field visit to Rwanda 
by the Papua AIDS Commission (22). The method now being used for voluntary male 
medical circumcision, PrepPex, is non-surgical and non-invasive, can be performed 
without anaesthetic, and produces less blood and fewer seams. It does not require 
special facilities or a doctor but can be performed  by a trained health worker (22). It is 
cheaper than surgery and takes only 5 minutes (22). 
 
In most provinces in Indonesia, circumcision is already popular because the majority 
of the population is Muslim. By contrast, in Papua and some other provinces (such as 
Bali and Nusa Tenggara Timur), which have predominantly non-Moslem populations, 
circumcision is very rarely practised (22). Accordingly, in 2012, the Papua AIDS 
Commission collaborated with religious and cultural leaders to explain the importance 
of circumcision and its compatibility with religious belief (22). 
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2.9 Intervention Strategies to Reduce HIV-STI among Sex 
Workers 
In 2015 the Indonesian Ministry of Health announced the implementation of a range of 
strategies to reduce HIV-STI in key populations, including FSW (42). The six pillars 
of these national STI and HIV strategies are discussed below.  
 
Coordination occurs at the national level between the Ministry of Health, National 
AIDS Commission, Ministry of Social Affairs, Ministry of Law, experts in HIV and 
STI, representatives from NGOs and key populations, police and the military (42,43). 
This takes the form of the Coordination Forum for Comprehensive STI-HIV Services 
(FK-LKB) which is facilitated by the Ministry of Health and meets every 6 months. 
 
Similar fora were also established at the provincial and district levels by the Ministry 
of Health, with the Provincial Department of Health acting as the facilitator. They 
contain representatives from the Provincial AIDS Commission, hospitals, key 
populations, and NGOs and are more practically oriented towards implementation than 
their counterpart at the national level.  
 
Through advocacy and provision of information, stakeholders have been involved in 
generating understanding and a supportive environment in sex work/brothel areas. This 
community involvement has proved to be valuable in reducing the prevalence of STI 
(22). 
 
Community involvement has also been important in reducing stigma, improving 
referral systems, and supporting groups and community-based health services. These 
in turn have helped to reduce the prevalence of HIV-STI and prevent transmission 
(22,42). Active involvement also means promotion of behavioural interventions to 
achieve safer sex practices through family-peer education. Mass and social media are 
also used to engage FSW and their families and communities in promoting condoms 
and prophylactic treatment to reduce STI transmission. 
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Resource management is very important in health services delivery and integration 
between programs helps to reduce  stigma (42,43). Examples of health service 
integration for key populations include integrated services for  TB-HIV and malaria, 
and ‘one roof-one day’ services. This type of integration allows members of high-risk 
populations to consult health providers with less fear of stigma and discrimination than 
would be the case at specialised sexual health clinics. The health providers themselves 
also experience less stigma in integrated services. 
 
The following are examples of key pillars for STI prevention and control in Indonesia 
(42): 
 A condom-based STI preventive program and STI treatment for adult or 
congenital infections 
 Strengthening of the government and private health system to provide better 
prevention and treatment services. 
 Strengthening the relationship between health service providers and FSW 
through outreach programs, peer education activities and community 
mobilisation.  
 
This aspect is closely related to the first pillar of coordination between stakeholders 
(42). The referral system consists of patient referral and specimen referral. Patient 
surveillance, conducted at a higher level, is essential to give feedback and monitor 
activity at lower levels. 
 
 Intensive treatment, including regular and routine STI checks for both 
symptomatic and asymptomatic FSW as well as periodic presumptive therapy 
(PPT) (42,43). 
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 Case-based treatment, involving both syndromic management (based on the 
symptoms experienced by the client and signs observed by the health care 
provider) and aetiological management (laboratory diagnosis is essential for 
aetiological management, where treatment and patient management are based 
on the specific cause of infection).  
 Screening  
 Periodic presumptive therapy is essential to reduce STI prevalence among key 
populations, especially FSWs. Indonesia has introduced some modifications to 
the latest PPT guidelines. 
Integration between behavioural and clinical interventions is essential to achieve long-
term results. Clinical interventions like PPT help to reduce STI prevalence within a 
specific group over a short period. In order to maintain low STI prevalence in the long 
run, however, behavioural interventions, including condom promotion, should also be 
implemented. 
Papua’s STI-HIV management approach is mainly adopted from national strategies on 
STI-HIV management. The key differences lie in the promotion of circumcision using 
the PrePex method to prevent HIV acquisition, and modifications to the STI guidelines. 
In most settings in Papua, syndromic management is used to treat STIs in the general 
population because of limited resources. In relation to key populations, especially 
FSWs, however, better collaboration between government and NGOs is needed to 
improve access to health services and HIV-STI testing.  
 
2.10 Conclusion 
The incidence of HIV and STI are remained major health concern in Indonesia, 
especially in Papua which the prevalence of HIV has reached generalised epidemic in 
general population. FSW is an important bridging population of STI and HIV given the 
number of other population is still very low and heterosexual transmission is 
predominant in Papua including Jayapura. Despite all strategies that have been 
implemented, the incidence of STIs were remain high in general population as well as 
among FSW especially undetected chlamydia and gonorrhoea which might increase the 
risk of HIV acquisition. Therefore, better strategies for screening proforma, diagnostic 
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test and treatment need to be implemented to reduce the incidence of STI especially 
gonorrhoea and chlamydia. This study is designed to study the prevalence of HIV-STI 
specifically undetected infection of gonorrhoea from Gram microscopy and chlamydia, 
to examine which behaviour related to chlamydia and gonorrhoea infection and to 
determine the routine test sensitivity in the clinic (Gram stain) with the gold standard 
of PCR to detect gonorrhoea infection. 
 
75 
 
Chapter 3 
3. Methodology 
 
This chapter describes study design and setting, sampling and recruitment of sample, 
material and methods used in the study, and how the study run by researcher as well as 
the laboratory test performed by the local lab and the lab in Jakarta (PCR). 
3.1 Study Design and Setting 
This cross-sectional descriptive study examined STI/HI prevalence and related 
behaviours among women working in entertainment venues in Jayapura City, 
Indonesia. It was conducted at the Centre for Reproductive Health (PKR) in Jayapura, 
Papua Province, Indonesia. The Centre is located in Wahno village, Abepura district in 
the middle of the Jayapura city and is relatively easy to reach by public transport or 
private vehicle. The fieldwork was conducted between August and October 2016. 
3.2 Sampling and Recruitment 
The study population comprised the 300-400 females who worked in entertainment 
establishments in Jayapura in 2016 and who regularly visited the Reproductive Health 
Centre (PKR) for HIV/STI check-ups, as required by law. Ninety five percent of the 
women who work in entertainment venues in Jayapura are non-Papuan, and only five 
percent of the population are Papuan. They come from other Indonesian islands such as 
Sulawesi, Sumatra and Java. They do not have any family or relatives in Jayapura and 
most of them migrated to Jayapura to work in entertainment venues. Every two to three 
months all the female workers are screened in the Centre for Neisseria gonorrhoeae 
(Gram stain of endocervical specimen), Trichomonas vaginalis (wet preparation of 
vaginal specimen), bacterial vaginosis, candidiasis and Treponema pallidum (RPR) and 
are given an HIV test (one rapid HIV test performed in triplicate).  
A representative sample for this population is 200 (to achieve 95% confidence level). 
Due to time constraints, however, only 176 samples were tested for Chlamydia 
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trachomatis and Neisseria gonorrhoeae using a molecular nucleic acid amplification 
test (NAAT) and 189 questionnaires were completed. 
The recruitment procedure was as follows. Two months prior to the study day, flyers 
containing brief information about the study were provided in the clinic’s waiting room. 
Nurses and clinic staff assisted by responding to any enquiries. Those clients who were 
interested in receiving initial contact from the researcher wrote their mobile number on 
the form placed on the receptionist’s desk. Women who declined to participate in the 
study continued to receive the usual standard of care provided by the clinic and were 
not disadvantaged in any way. 
On the study day, three study rooms were prepared in the clinic. After routine clinic 
registration and history-taking, clients were directed into one of these rooms. Each 
client received a brief explanation of the study from the researcher or one of the 
assistants. Those who expressed willingness to participate were given a copy of the 
participant information statement (Appendix 1) to read and a consent form (Appendix 
2) fill in and sign. Those who did not wish to participate were asked to stay for 
approximately 5 to 7 minutes and were given some information about HIV and STI 
prevention. They then proceeded to the examination room for the routine clinical 
assessment and testing process. 
 
 Women working in one of Jayapura’s entertainment venues (parlours, karaoke, 
bars, clubs) or any combination of these. 
 Aged 18 or over on the study day. 
 Working at least 3 months in the current establishment. 
 Agree to participate in the study, evidenced by giving voluntary signed consent. 
 
 Male or transgender 
 Working less than 3 months 
 Under 18 years on the study day. 
 Withdrew from the study. 
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3.3 Materials and Methods  
Data for this study were collected using questionnaires and laboratory reports.  
 
Variables included in the questionnaire were categorised into (appendix : 
 Demographic information (age, education level, marital status) 
 Obstetric-gynaecological information (pregnancy history, miscarriage 
history, age at first sexual encounter) 
 Behavioural information (duration of sex work, duration of working in the 
current venue(s), number of clients in the past week, regular sex partner, 
alcohol use, history of last regular HIV/STI screening, types of sexual 
activity (anal, oral, cunnilingus), use of protection during sexual activity 
(anal, oral, cunnilingus), condom use with clients, condom use with 
boyfriend/regular partner, periodic presumptive therapy). 
 Past infection (previous syphilis infection, tested and received results for 
HIV in the past year, had STI symptoms in the past year, had vaginal 
discharge in the last 5 years). 
The researcher recruited three PKR staff to administer the questionnaires. They 
received training on three different occasions to ensure they understood the 
requirements clearly.   
 
There were two main types of laboratory investigations - the routine tests conducted in 
the clinic and the C. trachomatis/N. gonorrhoeae combined NAAT which was 
conducted as a part of this study. 
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3.3.2.1 Routine tests performed in the Centre 
3.3.2.1.1 Blood tests 
HIV rapid test. The current HIV test used in the clinic is a triplicate rapid test. 
All clients are tested every 6 months; new employees who are tested on their first clinic 
visit. Before and after the test, each client receives counselling from a trained nurse or 
counsellor. As explained in Chapter 2, this is an immunoassay test that uses the same 
mechanism as the ELISA test (specific antibody detection) but in shortened form.  
The brands used in the clinic are SD Bioline HIV 1/2 3.0. 3rd Generation rapid test 
(Standard Diagnostics, Inc.), Triline rapid HIV test kit, and Oncoprobe Rapid HIV test, 
which are based on a direct sandwich method of antibody detection and are used as a 
triplicate test.  This assay can differentiate between HIV 1 and HIV 2 (WHO evaluation: 
100% sensitivity, 99.3% specificity; PEI (Paul Ehrtich Institute): 100% sensitivity, 
99,87 specificity) (93).  
 
The procedure was as follows :  
 The clinic staff member pricked client’s finger with a clean needle. 
 Using a capillary pipette, 20 µl of client’s blood was drawn and added to the 
round specimen well (marked S) on the test kit.  
 Another blood sample was then drawn and added to the second kit and the third 
kit. 
 Four drops of the assay were then added to each kit. 
 The result appeared in 10-20 minutes (figure 3.3.1). 
 If the result came up positive on both kits, then the result was positive. If only 
one kit came up positive, another kit was used as a confirmation test. 
 If there were 3 positives, the result was considered positive. If 2 were positive, 
another test was performed or referred for ELISA. If there was 1 positive, the 
triplicate test was re-done.  
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Figure 3.3.1 Rapid test HIV SD bioline (source : http://www.alere.com) 
Syphilis. The Rapid Plasma Reagin (RPR) test was used to detect syphilis 
infection. The clinic uses a qualitative RPR test which only differentiates between 
reactive and non-reactive, without quantifying the titer. The principle of this test (as 
explained in Chapter 2) uses an antibody feature which develops during the infection 
process. 
The procedure was as follows:  
 The RPR test card was labelled with the ID number. 
 2 ml of client’s blood was drawn using a 3 ml syringe and put into the centrifuge 
tube. 
 The blood was then centrifuged to obtain the clear plasma and allowed to stand 
for about 15 minutes to obtain the serum. 
 Using a clean disposable pipette, 50 µl of plasma was then added to the 18-mm 
circle on the RPR test card. 
 A toothpick was used to spread out the plasma to fill the entire circle.  
 The antigen in the syringe bottle was then shaken and held in a vertical position; 
several drops were dispensed to clear the needle of air. 
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 1 free-falling drop (17 µl) of antigen suspension was added to each circle 
containing serum. 
 The card was then placed on the mechanical rotator under a humidifying cover 
and rotated for about 8 minutes at 2 rpm. 
 The card was then removed from the rotator and briefly rotated and tilted by 
hand (3 or 4 motions). 
 The card could then be read according to the circle, either reactive or non-
reactive (Figure 3.3.2). If the result was reactive, the serum was tested using a 
rapid test. 
 
 
Figure 3.3.2 RPR test result  
(Source: https://labtestsonline.org) 
 
3.3.2.1.2 Vaginal specimen Wet film.  
The procedure was as follows: 
 Slide was labelled by the staff. 
 The swab stick was then rolled on a glass slide. 
 A few drops of potassium hydroxide (KOH) 10% were placed on the object 
glass before being covered. 
 The object glass was then examined under a microscope to see if there was any 
yeast (candida infection) or motile trichomonas vaginalis (trichomoniasis) or 
BV. 
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3.3.2.1.3 Endocervical specimen Gram stain.  
The procedure was as follows: 
 The slide was labelled with client’s clinic ID number. 
 The inoculated swab stick was rolled on a glass slide and left to dry. 
 The sample was fixed by passing the slide over a Bunsen burner two or three 
times. 
 The slide was placed on the staining tray, gently flooded with crystal violet, 
allowed to stand for 1 minute, then tilted and rinsed with tap water. 
 The slide was then gently flooded with Gram’s iodine and allowed to stand for 
1 minute, then tilted and rinsed with tap water. 
 The slide was then dipped into 95% ethyl alcohol or acetone for about 5 to 10 
seconds for decolourisation purposes then immediately rinsed with water. 
 The slide was then flooded gently with safranin to counter-stain, allowed to 
stand for 45 seconds and then rinsed with water. 
 Then the slide was blotted dry with paper and examined using a light 
microscope under oil-immersion to detect any gonorrhoea infection. 
3.3.2.1.4 2nd Endocervical specimen 
Nucleic Acid Amplification Test (NAAT). The Nucleic Acid Amplification Test 
for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) was performed in 
the Cipto Mangunkusumo laboratory at the University of Indonesia, Jakarta.  
The test used in this study was developed using SYBr Green real-time PCR for both 
NG and CT. The primers and procedure were adapted from two publications (94,95), 
both of which used TaqMan real-time PCR. In the present study, the laboratory 
modified this by using SYBr Green real-time PCR. PCR products for CT and NG were 
71 and 76 bp, respectively. The laboratory analysed the specificity of primers in 
Genbank and showed no cross-reaction with other microbes. Positive results were 
determined by melting curve analysis on a PCR machine.  
 
The PCR procedure was as follows:  
Sample preparation: 
  
82 
 
 In a 0.2-mL microcentrifuge tube, reaction mixes were prepared for all total 
samples to be transcribed. The volume of 4 tubes is shown in Figure 3.3.3  
 0.2-mL microcentrifuge tubes were labelled.  
 6–200ng (up to 3.475µL) of each total RNA sample was transferred to the 
corresponding microcentrifuge tube.  
 Each total sample was diluted to a volume of 3.475µL with RNase-free, 
deionised water.  
 Each tube was capped and gently tapped to mix the diluted samples.  
 The tubes were briefly centrifuged to eliminate air bubbles in the mixture.  
 Four 0.2-mL MicroAmp® Reaction Tubes were labelled for the four total RNA 
test samples. 
 A pipet was used to transfer 6.525µL of the reaction mix (from step1) to each 
labeled MicroAmp Reaction Tube.  
 Each 3.475µL diluted total sample was transferred to the corresponding 
MicroAmp reaction tube.  
 Each reaction tube was capped and gently tapped to mix the reactions.  
 The tubes were briefly centrifuged to force the solution to the bottom and 
eliminate air bubbles from the mixture.  
 Each reaction was transferred to a MicroAmp Optical 96-Well Reaction plate.  
 The MicroAmp plate was capped with a MicroAmp Optical cap.  
 The plate was centrifuged to spin down the contents and eliminate air bubbles 
from the solution. 
 
 
Figure 3.3.3 Preparation of reaction. 
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Thermal cycling:  
 The reactions were loaded into a thermal cycler.  
 The thermal cycler was programmed (Figure 3.3.4) with the following 
conditions: 
Begin transcription. 
IMPORTANT! After thermal cycling, store all cDNA samples at –15to –25°C. 
 
 
Figure 3.3.4 Thermal cycler programming. 
 
3.4 Study Procedure 
The layout of the clinic is shown in Figure 3.4.1  
 
Figure 3.4.1 Reproduction Health Centre Diagram 
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On the study day, the researcher made a brief announcement about the study while all 
clients were waiting for registration in the waiting room. Participant information 
statements and flyers were then handed out to all clients. 
In the registration room, all clients registered one by one and were then interviewed by 
the nurses as part of their routine check-up. Clients carried their medical record and 
were directed into one of the study rooms.  
 
In the study room, clients were given an explanation of the study, its benefits and risks. 
If they agreed to participate, they filled in and signed the participant consent form. A 
participant study number and code label were then generated and placed in the medical 
record. The researcher/assistant then handed the questionnaire to the participant for 
completion. If they preferred to be interviewed, the researcher/assistant helped them to 
fill in the questionnaire. Those who declined to participate stayed for about 5-7 minutes 
and were given information about STI infection prevention.  
 
In the examination room, the participants were confirmed by their identification code 
and study identification number on the medical record and sample tube before the 
samples were collected by the trained nurse or midwife. Each sample swab from the 
cervix was inserted into a sample tube whose label matched the medical record, then 2 
ml of NaCl was added to the tube. All the tubes were stored in the clinic’s fridge before 
shipping. 
 
At the end of the sample collection process, all clients (participants and non- 
participants) went back to the waiting room to wait for their doctor’s appointment. 
When each client’s routine screening test result became available, she was called to the 
doctor’s room for a one-on-one consultation to receive the result and treatment. Clients 
who received a positive result on the routine test were encouraged to inform their 
partner. 
Participants then proceeded to the pharmacist’s room to collect their medicine to treat 
any infection that had been identified from the routine screening test  
The overall procedure is illustrated in Figure 3.4.2 
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All codes and identification number labels were then removed from the medical record. 
All sample tubes were checked for labelling and damage. All tubes were packed and 
shipped by air cargo to the laboratory in Jakarta. 
 
Figure 3.4.2 Study flow 
The results of the NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoeae 
came back in November 2016. The identification numbers and two by four codes for 
positive participants were carefully recorded so these patients could be identified and 
recalled by the clinic for treatment. 
 
Data were entered into a database using Microsoft Excel 2013 (Microsoft Office Home 
and Student 2013, Microsoft Corporation © 2012), then transformed into an SPSS 
database. The Excel database was then transferred to Stata v. 14.1 (StataCorp, 2015) 
and analysed using bivariate and multiple logistic regression to determine correlations 
between the study variables (participant behaviour, clinical test result and any infection, 
particularly any endocervical infection. The bivariate and multiple logistic analyses 
were performed by Michael Walsh using Stata statistical software. The figures and 
tables were done by student researcher using Excel 2013 and SPSS v.16 (IBM, 2007). 
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3.5 Ethical Considerations and Study Benefits 
This study analysed routine laboratory screening test results, results of additional tests 
performed for the study, participant demographics and self-reported behaviour. The 
samples for the routine test were collected by nurses/midwives (genital samples) in a 
closed examination room and by laboratory technicians (blood samples) in the 
laboratory. Two by four codes and identification numbers were used instead of real 
names. Written consent was obtained from participants before they completed the 
questionnaire and before samples were collected. All paper files are securely stored in 
a locked filing cabinet and electronic data are stored securely in a password protected 
computer file. Only the principal investigator and supervisors have access to the study 
data. 
To ensure data confidentiality, every page of the questionnaire and study forms was 
given a unique identifier (two by four identification code and study identification 
number). These were recorded and stored in a locked filing cabinet, separate from the 
actual data on participants. 
Ethical approval was obtained from The Western Sydney Local Health 
District/University of Sydney Human Research Ethics Committee (Project No. 
2016/412). The local health department and clinic supervisor did not require further 
ethical approval. 
 
Participants benefitted by knowing their STI status and receiving treatment. 
Participants were offered an incentive in the form of a mobile voucher to the value of 
Rp. 50,000 (5AUD). Overall, of 43 participants who were found to be infected by N. 
gonorrhoeae or C. Trachomatis or both, 35 were recalled and treated. Five others had 
moved to other provinces; either they or their new clinic manager were notified of their 
results. The remaining three participants had not returned to the clinic because of 
transportation difficulties.  
 
This study will also benefit the at-risk population in Jayapura by providing evidence to 
inform local government policy-making and evaluation of the clinic’s procedures and 
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performance. This study’s findings can also be reported to the local community around 
the clinic to enhance their understanding of the clinic’s role in benefitting the local 
community and the wider population of Jayapura. 
 
The results of this study will be presented to the University of Sydney and at selected 
conferences. The results will be submitted as a Master’s thesis and published in national 
and/or international medical journals. The results and processes of the study will be 
reported to the local health department, clinic and ethical committee. 
 
The study will determine the prevalence of STIs among women who work in 
entertainment venues in Jayapura city. These data will assist the government and other 
stakeholders to evaluate the programs and strategies that have been implemented. The 
findings will inform policy, identify gaps in current programs and suggest strategies for 
improvement. 
 
 
The research partners in this project were The University of Sydney, the Centre of 
Reproductive Health Clinic (PKR) and Kota Jayapura, Cenderawasih University 
Medical Faculty. 
Most of the funding for the study came from a Western Sydney Sexual Health grant. A 
small amount was provided by the student and his employment institution. 
Funds were spent mainly on laboratory-based NAAT testing, courier costs, institutional 
and professional fees, and incentives. An institutional fee was paid to the clinic as a 
contribution to the service. Professional fees were for the research assistants, and 
participants received a small monetary incentive.  Details of the expenditures are 
presented in Table 3.5.1 
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Table 3.5.1 
Study Expenditures 
 
 
 
Category Amount 
(AUD) 
Quantity  Total 
Lab check  60 176  10,560 
Equipment and transport 150 1               
150 
Institutional fees 250 1               
250 
Professional fees 50 5  250 
Incentives 
(voucher/transportation) 
5 189  945 
Total     AUD  
12,155   
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Chapter 4  
4. Results 
 
 
This chapter describes all the result from the questionnaire, laboratory results and 
analysis. The data from questionnaire will be presented in the form of figures and tables 
while the laboratory result is showing the routine and additional test result. The analysis 
of this study is presented in tables of bivariate analysis and multiple logistic regression. 
 
 
4.1 Demographic Characteristics of Participants  
 
 The median age was 29 years, range 18-58 years (Table 4.1.1). 
 
Table 4.1.1  
Age of Participants (Years) (N=189)  
 
 
 
   
    
  
 
 
The bar chart of age groups in Figure 4.1.1 shows a non-normal distribution with a left 
skewness. This indicates that most participants were in the young adult (18-30 years) 
or middle aged (31-40 years) groups. The largest number of participants was in the 20-
24 years group; the number in each group decreases as age increases. 
Mean 30.3  
Median 29  
Range 40 
Minimum 18 
Maximum 58 
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Figure 4.1.1 Age distribution of participants (N=189). 
 
 
Of the 188 participants who answered the question about highest educational level, 40% 
had senior high school or above, 43% had junior high school only and 16% had primary 
level or no education (Figure 4.1.2). Overall, more than two-thirds (85%) of women 
working in entertainment venues in Jayapura had at least 12 years of education, which 
is the average education level in Indonesia (96). 
 
 
Figure 4.1.2 Education level of participants (N=188) 
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Figure 4.1.3 Marital status (N=189) 
 
Figure 4.1.3 shows that, among all participants, less than 10% (n=18) were currently 
married. Most participants (n=132, 69%) were divorced, and around 20% (n=39) were 
never married.  
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Figure 4.1.4 Employment duration in current establishment (N = 182) 
Overall, 55% of 182 women (100) reported working for more than six months in their 
current establishment; 45% (82) reported working for less than six months at the time 
of interview (Figure 4.1.4). 
 
  
Figure 4.1.4.1  Sex work duration (N = 176)  
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Less than a quarter (n=39, 22.2%) of the 176 women responded to the question about 
how long they had been working in the sex industry had been doing so for less than six 
months. Most women (n=71, 40%) had been engaged in sex work for more than 2 years. 
 
4.2 Obstetric-Gynaecological Histories 
 
The median age of the first sexual encounter among 187 participants was 18 years, 
range 10-34 years (Table 4.2.1). 
Table 4.2.1  
Age of First Sex (Years) (N=187) 
 
Mean 18 
Median 18  
Std. Deviation 2.8  
Range 24  
Minimum 10  
Maximum 34  
 
 
Figure 4.2.2 Pregnancy and miscarriage history (N=188) 
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More than 70% of participants (132) reported at least one pregnancy (Figure 4.2.2). 
Sixty-nine women (52%) of those with a pregnancy history reported more than one 
pregnancy; of these, 24 (38%) reported a history of miscarriage. Among the 63 women 
who reported only one pregnancy, 10 participants (16%) reported that the pregnancy 
resulted in a miscarriage. 
 
 
Figure 4.2.1 Ever diagnosed with syphilis (N=185) 
Overall, 176 of 185 women (95%) reported that they had not previously been diagnosed 
with syphilis, whilst nine women (5%) reported a previous syphilis infection. 
 
 
Figure 4.2.4 shows the small number of women who reported that they had symptoms 
suggestive of an STI in the past year, specifically, vaginal discharge, pain during sex or 
urination, blisters or ulcers, genital warts, rashes in the genital area, or genital itching. 
Out of 36 women who reported symptoms, 50% (18) sought medical treatment from 
clinics or private practices. Thirteen (36%) bought an antibiotic from a chemist without 
a prescription and the rest reported no treatment. None reported having visited a 
traditional healer for STI symptoms in the past year. 
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Figure 4.2.4  STI history in the past year and health seeking behaviour (N=188) 
 
 
 
 
Figure 4.2.5  Vaginal discharge in the past 5 years (N=185) 
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A history of vaginal discharge in the past five years was reported by 13% (24) of 
participants. Most of the women in this study (161, 87%) reported no history of vaginal 
discharge in the past five years. 
 
 
Figure 4.24.2.6   History of check-ups in the last 3 months (N=188) 
Figure 4.2.6  shows that more than two-thirds of participants (143, 76%) had at least 
one check-up in the last 3 months, while the other 45 (24%) did not. 
 
 
 
Figure 4.2.2.7   History of HIV testing (N=187) 
 
  
97 
 
HIV testing rates among this group of women was quite high (Figure 4.2.7). Overall, 
155 (83%) of 187 participants had been tested for HIV. Those testing within the service 
would have received their results at the same visit, as the clinic operates a rapid testing 
algorithm.  
 
4.3 Sexual Behaviour and Infection Prevention 
 
Table 4.3.1  
Number of Regular Male Partners (N=189) 
 
 
 
 
 
 
 
  Any Regular Male Partner 
Total   No Yes 
Marital 
Status 
Never married 15 (8%) 24 (12.6%) 39 (20.6%) 
Currently 
married 
12 (6.3%) 6 (3.1%) 18 (9.5%) 
Married before 81 (42.8%) 51 (27%) 132 (69.8%) 
Total 108 (57.1%) 81 (42.8%) 189 (100%) 
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Figure 4.3.1 Percentage having regular male partner by marital status (N=189) 
 
The number of participants who disclosed that they had a regular male partner 
(‘boyfriend’) was 81 (42%); the other 108 (58%) did not have any regular male partner 
(Table 4.3.1). Among the never married, 60% (24 women) reported that they had a 
regular sex partner. Among those who were divorced, 40% (51 women) reported that 
they had a regular male partner and among those who were currently married, 32% (6 
women) reported a regular sex partner (Figure 4.3.1). 
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Figure 4.3.2 Regular male partners in the past 1 year (N=182) 
Figure 4.3.2 shows that 60% of participants (109) indicated that they had had 
relationships with regular male partners in the last year.  
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Figure 4.3.3  Condom use with regular male partners (‘boyfriends’ (N=186) 
Another important variable is the use of a condom with regular male partners 
(‘boyfriends’). As can be seen from Figure 4.3.3, 80% of the women (149) were in 
relationships with regular male partners where condoms were not used. Of the 24 
women (20%) who reported using condoms, only one-third (8) reported consistent 
condom use; two-thirds (16) reported intermittent condom use.  
 
Table 4.3.4 
Number of Clients in the Last Week (N=171) 
 
Mean 2.54 
Median 2.0 
Mode 1 
Std. Deviation 2.4 
Variance 6.1 
Minimum 0 
Maximum 10 
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Figure 4.3.4  Number of clients in the last 1 week (N=171) 
Overall, the median number of clients in the last week was 2.5 and the mode was one 
client per week (Table 4.3.2). While the majority of women (101) reported less than 
three clients per week, 70 women (41%) reported four or more clients per week, and 5 
women (3%) reported 10 clients in the last week (Figure 4.3.4). 
 
 
 
Figure 4.3.5  Condom use with clients (N=180) 
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Consistent condom use with clients is an important variable in this study. Figure 4.3.5 
shows that only 67% of the women (121) always used condoms during sex with their 
clients. The remaining women used condoms with male clients sometimes or not at all.  
 
Anal sex was not reported as a frequent activity by participants, as shown in Table 4.3.6. 
More than 97% of participants (131) reported that they did not perform anal sex; only 
two women (1%) stated that they often had anal intercourse with clients. Condom use 
was infrequent among those women who engaged in anal sex. Only three women (2%) 
reported that they always used a condom while engaging in anal intercourse. 
 
Table 4.3.6 
Anal Sex and Condom Use on Anal Sex (N=135) 
 
 
 Condom Use While Receiving 
Anal 
Total   Never Rarely Always 
Anal Sex 
Activity 
Never 130 0 0 130 
Rarely 1 1 1 3 
Often 0 0 2 2 
Total 131 1 3 135 
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Figure 4.3.7.1  Frequency of giving oral sex (N=187) 
 
Figure 4.3.7.2  Condom use with oral sex (N=145) 
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Table 4.3.7  
Condom Use While Giving Oral Sex (N=145) 
 
  Condom Use While Giving Oral Sex 
Total   Never Rarely Often Always 
Give Oral 
Sex 
Never 109 0 0 0 109 
Rarely 8 10 1 3 22 
Often 7 0 1 4 12 
Always 2 0 0 0 2 
Total 126 10 2 7 145 
 
Compared to anal sex, oral sex was practised much more frequently by the participants. 
Overall, 41 (22%) of 187 women reported that they perform oral sex with their male 
clients. Only seven of 36 women (19.5%), however, reported that they always used 
condoms when performing oral sex (Table 4.3.7). 
 
 
Figure 4.3.8  Frequency of cunnilingus (N=184) 
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Figure 4.3.8.1  Dental dam/barrier use during cunnilingus (N=145) 
 
Table 4.3.8  
Dental dam use during cunnilingus (N=138) 
  Dental dam use during cunnilingus 
Total   Never Rarely Often Always 
Receive Oral 
Sex 
Never 112 0 0 0 112 
Rarely 8 5 0 1 14 
Often 7 0 3 1 11 
Always 1 0 0 0 1 
Total 128 5 3 2 138 
 
Cunnilingus was not frequently practised by the women. Only 26 women (18%) 
reported that they received cunnilingus from their sex partners. Only two women 
reported that they always used dental dams as barrier protection during cunnilingus 
(Table 4.3.8).  
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4.4 Other Factors Related to Infection Risk 
 
Alcohol consumption is perceived as a major contributing factor to high-risk sexual 
behaviour. Over half of the women (107, 57%) reported that they usually consumed 
alcohol before having sex (Figure 4.4.1). 
 
Figure 4.4.1 Alcohol consumption before sex in the last 3 months (N=188) 
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Figure 4.4.2 Sessional payment rates for short-encounter sex work (N=138)  
 
‘Short encounter’ refers to a sexual transaction between FSW and client usually lasting 
2-3 hours.  Figure 4.4.2 shows an interesting relationship between short-encounter 
payment rates and condom use. The majority of women (76, 55%) were being paid over 
750,000 rupiah (approximately AUD 75) for one short encounter session. Further 
analysis shows that the largest group of women were receiving the highest rate (>1 
million rupiah, AUD100), followed by women receiving 500,000-750,000 rupiah for a 
short encounter. The largest number of women who never used condoms was in the 
highest paid group (more than 1 million rupiah per transaction), which might indicate 
that clients are willing to pay more for unprotected sex.  
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Table 4.4.3  
Places used by Women for Sexual Transactions (N=85) 
 Hotel  Motel House Rented 
room/ 
work 
place 
Total 
Hotel 58 0 0 2 60 
Motel 0 1 0 0 1 
House 0 0 15 2 17 
Rented room/work 
place 
2 0 2 81 85 
Total 60 1 17 85  
 
Table 4.4.3 shows that rented rooms/workplaces were the preferred locations for sexual 
transactions, followed by hotels, houses and motels. Only one woman reported that she 
worked from a motel room. 
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4.5 Laboratory Test Data  
 
Chlamydia and gonorrhoea were detected in 13.6% and 15.3% of women, respectively; 
overall, 24.4% of women were infected with one or both of these STIs (Table 4.5.1). 
Eight women were dually infected with gonorrhoea and chlamydia on endocervical 
testing by NAAT. However, the number of cases of trichomoniasis was relatively low 
(6.2%), and the number of syphilis cases was even lower at less than 1%. 
 
a. Routine test 
Table 4.5.1.1 
Routine STI Screening Results  
STI/other infection/ 
infection indicator 
Total  
(N) 
Positive/reactive/  
>= 30/hpf (PMN) 
Negative /non-reactive/ 
<30/hpf 
HIV (rapid test) 189 0 0 % 189 100 % 
Syphilis (rapid test 
and RPR) 
188 1 0.5 % 188 99.5 % 
Pus cells on Gram 
stain (endocervical 
sample) 
179 72 40.2 % 107 59.8 % 
Gram negative 
diplococci visualized 
(endocervical 
sample) 
180 4 2.3 % 176 97.7 % 
Trichomonas 
vaginalis (wet film, 
vaginal sample) 
176 11 6.2 % 165 93.8 % 
Candida spp. (Gram 
stain, vaginal 
sample) 
176 5 2.8 % 171 97.2 % 
Bacterial vaginosis 
(Gram stain, vaginal 
sample) 
176 82 46.6 % 94 4.4 % 
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b. Specific study test 
Table 4.5.1.2 
Specific Study Test Results  
Chlamydia 
trachomatis (NAAT) 
176 24 13.6 
% 
152 86.4 % 
Neisseria 
gonorrhoeae (NAAT) 
178 27 15.3 
% 
149 84.7 % 
Chlamydial and/or 
gonococcal 
endocervical infection 
(NAAT) 
176 43 24.4 
% 
133 4.5 % 
 
 
As can be seen in Table 4.5.3. , the sensitivity of the Gram microscopy test for 
presumptive diagnosis of gonorrhoea, through demonstration of Gram negative 
diplococci on the slide, setting was 3.7% compared to the gold standard of the Nucleic 
Acid Amplification Test (NAAT) using PCR. The specificity of the Gram microscopy 
test in this setting was 97.9% compared to PCR test (gold standard). The positive 
predictive value (PPV) was only 25% and the negative predictive value (NPV) was 
84.6%.  
Table 4.5.2.1  
Cross-tabulation microscopy Gram and NAAT 
   NAAT Gonorrhoea 
Test  
Total    Negative Positive 
Microscopy test for  
Gram Negative 
Diplococci 
Negative Count 143 26 169 
Positive Count 
3 1 4 
Total Count 146 27 173 
 
 
The sensitivity of using polymorphonuclear leucocyte (PMNL) count to predict 
gonorrhoea infection in the endocervix was only 44.4% compared to the NAAT result 
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gold standard (Table 4.7.3). The specificity of the PMNL count was 60.4% compared 
to NAAT. The PPV was 16.9% and the NPV was 83.1%. 
Table 4.5.2.2. 
Cross-tabulation of PMNL Count Compared to NAAT to Predict Gonorrhoea Infection 
   NAAT Gonorrhoea 
Test  
Total    Negative Positive 
Number of PMNL on 
endocervical smear 
<30/hpf Count 90 15 105 
>=30/hpf Count 59 12 71 
Total Count 149 27 176 
 
The sensitivity of using polymorphonuclear leucocyte (PMNL) count to predict 
chlamydial infection in the endocervix was only 54.2% compared to the NAAT result 
gold standard (Table 4.7.4). The specificity of PMNL count was 61.8% compared to 
NAAT. The PPV was 18.3% and the NPV was 89.5%. 
  
Table 4.5.2.3 
Cross-tabulation of PMNL Count Compared to NAAT to Predict Chlamydial  
Infection 
   NAAT Chlamydia 
Test 
Total    Negative Positive 
Number of PMN on 
Cervix 
<30/hpf Count 94 11 105 
>=30/hpf Count 58 13 71 
Total Count 152 24 176 
 
 
The sensitivity of using the PMNL count to predict either gonorrhoea or chlamydia 
infection in the endocervix was 48.8% compared to the NAAT gold standard (Table 
4.13). The specificity was 62.4% compared to NAAT. The PPV was 29.6% and the 
NPV was 79%. 
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Table 4.5.2.4. 
Cross-tabulation of PMN Count Compared to NAAT to Predict Gonorrhoea and/or Chlamydia 
Infection 
   NG/CT Infection of 
Endocervix  
Total    No Yes 
Number of PMNL 
on endocervical 
smear 
<30/hpf Count 83 22 105 
>=30/hpf Count 
50 21 71 
Total Count 133 43 176 
NG : Neissheria gonorrhoeae 
CT : Chlamydia trachomatis  
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4.6 Correlation Analysis  
 
Table 4.6.1 shows bivariate analysis of age, the age of 1st sexual intercourse, number 
of client in the last week with the infection in endocervix (either chlamydia or 
gonorrhoeae) to see any correlation between these variables with the outcome of 
endocervical infection. 
 
Table 4.6.1.1. 
Bivariate analysis (t-test) of correlation between numerical variables with endocervical 
infection 
Variable Mean  Mean 
difference 
St. Error P value 95% CI 
Age 27.62 3.94 0.97 0.0062 25.6 – 
29.6 
Age of 1st sexual 
intercourse 
17.68 0.47 0.52 0.372 16.6 – 
18.7 
Number of client in the 
last week 
1.8 1.02 0.34 0.0286 1.1 – 2.5 
 
 
The correlation between behavioural, other test result variables and infection in the 
endocervix is shown in Table 4.6.1.2.  
Table 4.6.1.2. 
Bivariate analysis (t-test) of correlation between ordinal variables with endocervix 
infection  
Variable Compared 
to  
Odds 
ratio 
St. Error P value 95% CI 
Marriage Status Never 
married 
    
Current  3.5 2.289 0.049 1 – 12.5 
Previous  1.16 0.5530 0.745 0.46-2.95 
Regular Sex Partner No regular 
partner 
    
  
114 
 
Married + have regular 
partner 
 1.50 0.533 0.24  
Not married + have 
regular Partner 
 0.26 0.066 0.00 0.16 – 
0.43 
Pregnancy History Never 
pregnant 
    
Once   1.73 0.81 0.24 0.69 – 
4.36 
More than Once  1.78 0.82 0.21 0.72 – 4.4 
Miscarriage  Never get 
miscarriage 
1.64 0.68 0.234 0.72 – 
3.73 
Last education No 
education 
/elementary 
    
Junior High School  1.62 0.97 0.43 0.49 – 5.3 
Senior High School  3.10 1.90 0.051 0.99 – 
10.3 
Sex Work Duration Less than 6 
months 
    
6 to 24 months  0.60 0.29 0.296 0.23 – 
1.55 
More than 24 months  0.50 0.24 0.16 0.19 – 
1.29 
Duration of Work in the 
Current Place 
Less than 6 
months 
    
More than 6 months  1.12 0.42 0.749 0.54 – 
2.33 
Regular Male Partners in the 
Last 1 Year 
Not having 
regular 
male 
partner in 
the past 1 
year 
2.8 1.23 0.017 1.20 – 
6.67 
Condom with Clients Never use 
condom 
    
Sometimes  0.41 0.40 0.36 0.06 - 2.76 
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Always  0.62 0.39 0.45 0.17 – 
2.14 
Condom with Regular Male 
Partners 
Never use 
condom 
    
Sometimes  0.71 0.44 0.59 0.21 – 
2.43 
Always  0.78 0.68 0.78 0.14 – 
4.30 
Vaginal Discharge in the Last 
5 Year 
No vaginal 
discharge 
3.51 1.69 0.009 1.37 – 
9.03 
Past History of Syphilis No syphilis 2.50 1.96 0.24 0.53 – 
11.69 
Alcohol Before Sex in the 
Last 3 Months 
No alcohol 
use 
1.06 0.37 0.86 0.52 – 
2.14 
Sexual Health Check-up in 
the Last 3 Months  
No check-
up 
0.59 0.23 0.18 0.27 – 
1.29 
STI Symptoms in the Past 1 
Year  
No 
symptom 
1.83 0.75 0.13 0.82 – 
4.09 
Previous STI Therapy  No 
medication 
    
Self Medication  1.31 0.79 0.64 0.40 – 
4.29 
Seek for Medication   1.58 0.70 0.30 0.66 – 
3.76 
History of HIV Test  No  0.41 0.18 0.045 0.17 – 
0.98 
Short Encounter Payment 
Rates  
Less than 
500k 
rupiah 
    
500k-750k Rupiahs  1.33 1.01 0.70 0.29 – 
5.95 
750k-1million Rupiahs  2.22 1.79 0.32 0.45 – 
10.79 
More than 1 million 
Rupiahs 
 2.85 1.97 0.12 0.73 – 
11.08 
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Hotel  Non hotel 2.21 0.80 0.029 1.08 – 
4.53 
Rented Room / Work Place  Non rent 
room 
0.34 0.13 0.007 0.16 – 
0.74 
House  Non house 0.21 0.23 0.15 0.02 – 
1.73 
Anal sex Never     
Rarely  7.13 8.83 0.11 0.62 – 
80.88 
Giving oral sex Never     
Rarely  1.30 0.63 0.58 0.49 – 
3.40 
Often  1.00 0.69 0.99 0.26 – 
3.88 
Always   3.35 4.79 0.39 0.20 – 
55.20 
Condom on oral sex Never     
Rarely  0.34 0.36 0.31 0.04 – 
2.81 
Often  3.07 4.39 0.43 0.18 – 
50.73 
Always   0.51 0.56 0.54 0.05 – 
4.43 
Receiving cunnilingus Never     
Rarely  1.84 1.00 0.26 0.63 – 
5.36 
Often  1.01 0.69 0.98 0.26 – 
3.90 
Always   1 Empty    
Dental dam with cunnilingus Never     
Rarely  0.83 0.94 0.87 0.08 0 
7.77 
Often  1 Empty   
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Always   3.33 4.77 0.40 0.20 – 
55.08 
 
The conclusion of variables with significant correlation from Table 4.6.1.2 related to 
any endocervical infection is provided in Table 4.6.1.3.  
Table 4.6.1.3. 
Significant bivariate analysis (t-test) 
Variable Compare 
to  
Odds 
ratio 
St. Error P value 95% CI 
Marriage Status Never 
married 
    
Current  3.5 2.289 0.049 1 – 12.5 
Previous  1.16 0.5530 0.745 0.46-2.95 
Last Education No 
education 
/elementary 
    
Junior High School  1.62 0.97 0.43 0.49 – 5.3 
Senior High School  3.10 1.90 0.051 0.99 – 
10.3 
Regular Male Partners in the 
Last 1 Year 
Not having 
BF in the 
past 1 year 
2.8 1.23 0.017 1.20 – 
6.67 
Vaginal Discharge in the Past 
5 Year 
Never had 3.51 1.69 0.009 1.37 – 
9.03 
History of HIV Testing No  0.41 0.18 0.045 0.17 – 
0.98 
Hotel  Non hotel 2.21 0.80 0.029 1.08 – 
4.53 
Rent Room / Working Place  Non rent 
room 
0.34 0.13 0.007 0.16 – 
0.74 
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All the variables from the bivariate analysis pooled together and analysed using 
multiple logistic regression. The result is shown in Table 4.8.4 
 
Table 4.6.2. 
Multiple logistic regression (t-test) 
 Chlamydia 
and/ or gonorrhoea 
infection  
Odds Ratio St. Error P value 95% CI 
Age 0.92 0.03 0.042 0.84 – 0.99 
Marriage Status     
Current 9.14 8.11 0.013 1.60 – 52.03 
Previous  5.02 3.50 0.021 1.20 – 19.74 
Last Edu     
Junior High 
School 
0.71 0.55 0.664 0.15 – 3.32 
Senior High 
School 
1.43 1.12 0.649 0.30 – 6.71 
Number of Client in 
the last week 
0.84 0.10 0.154 0.66 – 1.06 
Regular Male 
Partner in the last 1 
year 
2.43 1.34 0.109 0.82 – 7.19 
Condom Use With 
Client 
1.38  0.95 0.635 0.36 – 5.33 
Vaginal Discharge 
in the Past 5 Year 
4.52 2.66 0.010 1.43 – 14.34 
History of HIV 
testing  
1.45 1.02 0.595 0.36 – 5.78 
Place Hotel 1.48 0.86 0.503 0.46 – 4.66 
Place Rentroom 0.91 0.60 0.897 0.24 – 3.37 
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As we can see from table 4.6.2., the pooled data from the logistic regression shows a 
consistent statistical correlation between the age of participant (young age), marital 
status (currently and previous marriage), and the history of vaginal discharge in the last 
5 years with endocervical infection. The other variables listed had a significant 
correlation in the bivariate analysis only.  
4.7 Conclusion 
Women working in entertainment venues in Jayapura who were seen at the clinic for 
sexual health screening in 2016 had an average age of 30.3 years. The majority had an 
average standard education (12 years), were divorced, and had engaged in sex work for 
more than 6 months. They had a young age of first sex, had been pregnant at least once, 
and reported low numbers of miscarriages. They had experienced vaginal discharge in 
the past 5 years, but had not previously been diagnosed with syphilis.  
 
The participants reported an average of around 2.5 clients per week. The majority had 
had a check-up in the last three months and were tested for HIV. More than half 
acknowledged that they consumed alcohol prior to sex. The majority received high 
payment for short term sex and preferred to use hotels for sex transactions. Two-thirds 
reported regular condom use with male clients, but less than 10% regularly used 
condoms with their own sexual partners. They reported a low prevalence of anal and 
oral sex and cunnilingus, with a low utilization of barrier methods of protection. 
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Chapter 5 
5. Discussion 
 
This study used Nucleic Acid Amplification Test (NAAT) procedures to generate data 
on the prevalence of chlamydia and gonorrhoea among indirect sex workers in 
entertainment venues. This is the first time such data have been available over the last 
five years.  This chapter summarises the study’s main findings and discusses their 
implications in the context of similar studies in Indonesia and elsewhere. The 
limitations of the study are considered and recommendations for future research are 
proposed. 
 
5.1 Summary of Major Findings 
 
The questionnaire used in this study collected important demographic and behavioural 
data about participants’ education level, condom use with clients and regular sex 
partners, income from sex work, and non-genital to genital sexual practices.  
Most of the respondents had at least graduated from junior high school, which is the 
national standard of education. Among those who failed to achieve this ideal level, only 
10% (n=3) used condoms inconsistently. There was no significant correlation between 
the education level and consistent condom use. The finding that the level of education 
does not correlate with the level of inconsistent condom use agrees with findings from 
a study undertaken among FSW in Uganda, where most are uneducated (97). However, 
in the Ugandan study, inconsistent condom use among FSWs was significantly related 
to poverty (needs driven), partner refusal, alcohol before sex and beliefs that condom 
will kill the sex mood rather than education status (97). The proportion of women who 
consistently used condoms with their clients was higher than the proportion of those 
who consistently used condoms with their regular sex partner. This finding is consistent 
with those from other studies (98,99).  
More than half of the participants reported alcohol consumption prior to sexual activity.  
Alcohol use during work mainly occurred in the karaoke and bar venues and is likely 
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to reflect the nature of these businesses, where escort tips are based on how many bottles 
the clients buy. Hence the women have to accompany the customer in his drinking; on 
occasions, they are also forced to drink either by the customer or the business owner  
(to increase the number of alcohol bought by the customer). Similar circumstances have 
been reported in other settings, for example in Senggigi in West Nusa Tenggara, 
Indonesia (100). There was, however, no significant association between alcohol 
consumption and consistent condom use or risk of acquiring STI. Similar findings were 
reported in a systematic review of 11 studies (101). The alcohol findings are discussed 
in more detail below.  
Non-genital to genital sexual practices were not popular among sex workers in this 
setting. Oral sex, cunnilingus and anal sex were only practised by a small number of 
participants, and consistent condom use for these activities was also very rare. 
 
Laboratory test results consisted of routine HIV and STI screening in the reproductive 
health centre and study-specific additional screening for C. trachomatis and N. 
gonorrhoeae with NAATs in the Jakarta-based laboratory. 
The percentages of infection with HIV, syphilis, trichomoniasis and gonorrhoea were 
lower than those reported in the 2011 IBBS (the number of cases of trichomoniasis was 
not measured in the 2011 IBBS) (9). This finding could represent a possible 
improvement, although the fact that this study was conducted in a different location 
from the IBBS in 2011 makes it impossible to compare the data due to potential 
population differences. Any improvement could potentially be a result of the 
implementation of local regulation No. 16 (2011) that requires regular screening among 
women working in entertainment venues in Jayapura (102). 
The prevalence of gonorrhoea diagnosed by NAAT was almost six times higher than 
the number of cases detected by Gram-stained microscopy at the reproduction health 
centre. This indicates that the sensitivity of Gram-staining of endocervical smears was 
lower than findings from previous studies (103,104) in which microscopy was 
compared with NAAT testing. In these studies, the sensitivity of Gram microscopy 
compared with NAATmvaried in different settings; the sensitivity was between 20% 
and 30% sensitivity compared to 15% in the present study (103,104).  
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The test results identified two predictors of cervicitis caused by N. gonorrhoeae and C. 
trachomatis - the PMNLs (leukocytes) count and bacterial vaginosis. Bacterial 
vaginosis was a better predictor of any endocervical infection compared to PMNL 
counts. However, since the BV usually only occurs around the vaginal area and the 
present study found no significant correlation between BV and endocervical infection, 
this finding needs to be examined in future research to determine if BV can be a good 
predictor of endocervical infection. 
Other studies on predictors of endocervical infection (105,106) found the PMNL count 
showed a moderate sensitivity and specificity compared to NAAT. The risk of having 
accompanying cervicitis was also three times more likely in those with raised PMNLs 
compared to those without a significant leukocyte count. Individuals with bacterial 
vaginosis are more likely to have co-existent gonorrhoea (four times likelihood) and 
chlamydia infection (three times likelihood), respectively (106).  
Almost one-quarter of the participants were infected with C. trachomatis. This 
prevalence is quite high compared to other parts of Indonesia (107), especially the 
western area of the country which has a prevalence of between 18% and 7%.  In the 
east of Indonesia, however, chlamydia infection rates remain high (26.7%) (108) 
 
According to the bivariate analysis, those women who were currently married were 
most likely to have an endocervical infection with either N. gonorrhoeae or C. 
trachomatis. This may reflect higher needs of money to support children which is 
consistent with some studies (97,109,110) that highlight poverty or lower work income 
as factors which significantly reduce women’s bargaining power to use condoms.  
Although having a recent regular sex partner was not significantly associated with 
acquiring an endocervical STI, having a boyfriend in the past 1 year was significantly 
correlated. This finding is consistent with some studies (111,112) which found a 
correlation between having a regular sex partner and having an STI, caused by a low 
level of consistent condom use with regular sex partner especially non-paying one. One 
such study (106) even reported that having a new regular sexual partner in the past 3 
months was significantly related to STI acquisition. 
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Another interesting finding concerns the correlation between age and any infection in 
the endocervix. The younger group (i.e. those aged 27 years or less) was more at risk 
of acquiring infection than the older women. These findings are consistent with a 
previous finding (113) which showed that young people were at more risk of 
contracting chlamydia or gonorrhoea which cause cervicitis. The other two studies 
found that endocervical infections, especially chlamydia, were more prevalent among 
younger women, and suggested that the mean age of those at risk was 25 years or 
younger (114,115). Some studies also suggested a younger mean age (around 20 years 
or younger) was associated with higher risk of acquiring endocervical infections 
(98,106,108). Inexperience of condom negotiation, and poverty and tendencies of 
having more clients were reported as the causes of this phenomenon. 
The age of first sex (coitarche) was also examined in this study. There was no 
significant correlation between the age of first sex and risk of contracting any 
endocervical infectionHowever, in another study, a lower coitarche was related to the 
risk of acquiring cervical cancer (116). Elsewhere, coitarche was reported as an 
independent risk factor for the presence of gonorrhoea and chlamydia among female 
sex workers, particularly in Indonesia (10). 
  
A UK based study of sex workers concluded that bacterial infection (gonorrhoea) was 
associated with the number of non-commercial contacts/partners and lower condom use 
with non-commercial contacts (117). In other geographical settings, such as Cambodia 
(109) and Senegal (99), consistent condom use had a significant correlation with 
reduced risk of acquiring STIs, particularly gonorrhoea and chlamydia. Therefore, 
although the present study found no correlation with the use of condoms, it is important 
to note that this finding is in contrast with those from other studies that reported a 
significant correlation with the risk of acquiring any endocervical infection. This 
difference might result from the relatively small sample size in the present study. 
There did appear to be a statistically significant correlation between a history of vaginal 
discharge and having any endocervical infection, in keeping with other studies.One 
study(106) indicated that bacterial vaginosis, as the most common cause of vaginal 
discharge, can be a predictor of endocervical chlamydia or gonorrhoea. This might 
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explain why vaginal discharge was significantly correlated with the risk of acquiring 
gonorrhoea and or chlamydia in the present study. 
Alcohol has been identified as a factor associated with high-risk sexual conduct and 
STI acquisition (101). In this study, however, alcohol was not considered statistically 
significant in relation to acquiring endocervical infections. This finding is supported by 
a systematic review of 11 studies, published in 2005. Very few studies have specifically 
examined the relationship between alcohol and sexually transmitted diseases, yet most 
have not found a significant association. This might be explained by the fact that there 
is a wide range in the amount of alcohol consumed, from a small sip to a few ounces, 
and that there is individual variation in alcohol tolerance (101). 
There was no significant association between short-term sexual payment rates and 
endocervical infection. Figure 4.6.2, however, shows that most women were paid less 
than 1 million rupiahs (100 AUD) per short term transaction but the largest number of 
women who never used condoms with clients were those who earned more than 1 
million rupiahs. A study, undertaken in 1999, reported that not having a regular salary 
increased the risk of acquiring gonorrhoea up to two times compared to those who did 
have a regular salary (118). This finding shows that salaries can vary widely, and have 
no regular income will affect the risk of acquiring any endocervical infection. Another 
study (109) found that high income sex workers tended to use condoms more 
consistently than low income sex workers. This might be related to their relative 
bargaining positions over condom use with clients. 
The current study reports that those women who transact sex business in hotels have 
twice the risk of acquiring endocervical infections compared to those who do not use 
hotels. Other studies that were reviewed did not examine this variable. Clients use 
hotels have more money and usually have more power to negotiate not using condoms. 
Women in need of earning more money (poverty) might be particularly vulnerable if 
they have room bills to pay (97). 
There was no significant statistical correlation between anal sex, fellatio and 
cunnilingus activities and the risk of acquiring endocervical infection, and the 
prevalence of these practices was very low. The use of protection during these activities 
was also low and had no significant statistical correlation.  
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In summary, behavioural data highlight several important findings related to the 
detection of endocervical STIs among women working in entertainment venues in 
Jayapura. Age, marital status, highest education level, having a regular sex partner, 
history of vaginal discharge in the last 5 years, number of clients weekly, regular HIV 
testing, and using hotels and rented rooms for sexual transactions were significantly 
related to infection with chlamydia and/or gonorrhoea among women working in 
entertainment venues in Jayapura. 
 
The results of all the bivariate analyses were pooled together and examined using 
statistical software to determine which variables were still significantly related 
chlamydial and/or gonococcal endocervical infection.  
Through use of multiple logistical analysis, we determined that only three out of nine 
variables identified as significant in the initial bivariate analysis retained significance 
with the presence of chlamydial/gonorrhoea endocervical infection. Those variables 
were age, marital status and a past history of vaginal discharge.  
 
Older women were less likely to have a chlamydial/gonorrhoea infection than young 
women, consistent with the other previous studies (113–115). Young women tend to 
have more clients compare to older women which make them have a higher chance to 
contract infections. Young women also tend to have less experience to negotiate 
condom use compare to the older group. 
The risk of chlamydial/gonococcal endocervical infections in currently married women 
was nine times higher than in never-married women and five times higher than in 
women who were not currently married but had been married before. The possible 
reason of these circumstances may be because currently married women frequently 
have higher financial expenses than non-married women and that they may need to 
more money. Accordingly, they may be more willing to take risks during sex and 
acquire endocervical STIs.   Women who reported having vaginal discharge in the last 
five years were at four times higher risk of infection with chlamydia and/or gonorrhoea 
than those women who did not report having a vaginal discharge in the same time 
period. This finding is consistent with other studies (114,119) which reported having a 
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suspected recurrent vaginal discharge and pelvic inflammatory diseases in the last 
couple of years have a significant association with gonorrhoea or chlamydia infections. 
 
 
5.2 Implications of the Findings 
This study has generated some interesting findings, which can provide useful baseline 
data for policy makers to evaluate the effectiveness of the implementation of the 
HIV/STI control program.  These are discussed in more detail below. 
First, a high prevalence of STI infections (more than 20%), particularly gonorrhoea and 
chlamydia, was observed in this study. This fact, and the observation that microscopy 
performed poorly as a means of detecting endocervical infection provides evidence of 
the need to replace endocervical microscopy with a better screening test to detect 
infection and to revitalise the periodic presumptive therapy program among the women 
attending the reproductive health centre. 
Second, an algorithm of gonorrhoea and chlamydia NAAT testing for female sex 
workers in this setting needs to be introduced so that asymptomatic infections are 
diagnosed and treated in a timely manner.  
Third, more education needs to be delivered to female sex workers. This education 
should include topics such as STI-HIV prevention and management, healthy sexual 
practice, and condom negotiation skills for the workplace.  
Finally, gonococcal culture for detection of antimicrobial resistance needs to be 
implemented to prevent the spread of resistant gonococci in both the general and at-risk 
populations. 
 
5.3 Limitations of the Study 
Several limitations of the present study can be identified. These include: 
 The sample size was limited by the time available for field work (16 weeks).  
 With hindsight, the study questionnaire could have included some additional 
key items, such as questions about douching habits, condom use in the last 
sexual activity (client and non-paid regular sex partner) and working venues.  
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 The reasons for inconsistent condom use were not well explored in the 
questionnaire. 
 The periodic presumptive therapy (PPT) variable was eliminated from the data 
analysis due to inconsistent and less than ideal PPT implementation in the 
centre.  
 Histories of recreational drug use and sexual abuse were excluded from the 
questionnaire because this information might have legal implications for both 
researcher and respondents. 
 
5.4 Recommendations for Future Research  
More research is needed to address some key questions that emerged from the study. 
These include: 
 What is the prevalence of other sexually transmitted causes of endocervical 
infection, such as Mycoplasma genitalium ? 
 What are the reasons for the observed reluctance of female sex workers and 
their clients to use condoms during sexual activity? 
 Why and when does periodic presumptive therapy need to be initiated and 
stopped in this setting? 
 What are the biological predictors for endocervical infection among female sex 
workers? 
 What is the best screening algorithm for women in an era of NAATs? 
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Appendix 1 Participant Information Statement 
 
 
 
  
Master of Philosophy 
Sydney Medical School 
  
 ABN 15 211 513 464 
 
  David Lewis   
 Professor, FRCH (UK) FAChSHM PhD 
  
Director Room 
 Western Sydney Sexual Health 
NSW 2006 AUSTRALIA 
Telephone:   +61 2 9762 5388 
Facsimile:  +61 2 97625387 
Email: david.lewis2@sydney.edu.au 
Web:http://www.sydney.edu.au/medicine/wsshc 
 
Prevalence of HIV - STI among Women Working in Entertainment Venues (Parlours, Karaoke, 
Clubs, and Bars) in Jayapura, Papua - Indonesia  
 
PARTICIPANT INFORMATION STATEMENT 
 
(1) What is this study about? 
 
You are invited to take part in a research study about infection rate of HIV - STI and 
their association with risk behaviour among the population of women working in 
entertainment venues. 
 
You have been invited to participate in this study because you are fit with the criteria 
of the study participant, which is women age 18 plus who have been working in the 
entertainment venues for a period of at least 3 months. This Participant Information 
Statement tells you about the research study. Knowing about what is involved will 
help you decide if you want to take part in the research. Please read this sheet 
carefully and ask questions about anything that you do not understand or want to 
know more about.  
 
Participation in this research study is voluntary.  
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By giving your consent to take part in this study you are telling us that you: 
 Understand what you have read. 
 Agree to take part in the research study as outlined below. 
 Agree to the use of your personal information as described. 
 
You will be given a copy of this Participant Information Statement to keep. 
 
(2) Who is running the study? 
 
 The study is being carried out by the following researchers: 
1. David Lewis Profesor, FRCH (UK) FAChSHM PhD 
2. Gerson Andrew Warnares, dr. 
 
dr. Gerson Andrew Warnares is conducting this study as the basis for the degree 
of Master of Philosophy at The University of Sydney. This will take place under the 
supervision of Prof. David Lewis, Profesor of Marie Bashir institute & Director of 
Western Sydney Sexual Health Centre. 
 
This study is being funded by grant and some portion allocated from the 
researcher tuition from Australian Award Scholarship by the Western Sydney 
Sexual Health Centre- Sydney Medical School.  
 
 
(3) What will the study involve for me? 
 
A. Routine HIV & STI (trichomoniasis, gonorrhoea, and syphilis) testing will take 
place as per routine standard of care. 
B. In addition you will be asked to : 
- Fill an informed consent about your approval to involve in this study, your 
permission about the researcher will have a look to your lab result, and 
medical record. 
- Allow the trained nurse in the examination room, to obtain another swab 
from your cervix during sample collection for additional gonorrhoea and 
chlamydia testing.  
- Fill a questionnaire, which will be about your identity, behavioural 
information, and knowledge about HIV-STI. If you have difficulties on 
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reading the questionnaire, trained nurse or doctor will read it for you and 
show you how to fill the questionnaire. 
C. Your laboratory result from the Reproduction Health Centre (Pusat Kesehatan 
Reproduction-PKR) clinic Jayapura and molecular test in Jakarta will be 
obtained from your medical record and from the lab report, and this result will 
be used as the basic data of STI and HIV prevalence. 
D. If you have positive HIV or STI test, you will be counselled appropriately and 
receive any necessary treatments free of charge in accordance with national 
HIV – STI treatment guidelines. 
 
(4) How much of my time will the study take? 
 
It will spend about 16-26 minutes, first 5-10 minutes to read and sign the consent 
form, 1 additional minutes in the examination room and another 10-15 minutes 
to fill up the questionnaire.  
 
(5) Who can take part in the study? 
 
All women age 18 or older working in one or combination of entertainment venues 
in Jayapura for a minimum of 3 months period and clients of the Reproduction 
Health Centre (PKR) Clinic Jayapura. 
 
(6) Do I have to be in the study? Can I withdraw from the study once I've started? 
 
Being in this study is completely voluntary and you do not have to take part. Your 
decision whether to participate will not affect your current or future relationship 
with the researchers or anyone else at the clinic. 
 
If you decide to take part in the study and then change your mind later, you are 
free to withdraw at any time. You can do this by reporting to the researcher, the 
clinic’s doctor or nurse through verbal or text message. 
 
You are free to stop filling up the questionnaire at any time. Any written 
information will be erased and the information you have provided will not be 
included in the study results unless you say that you want us to keep them. You 
may also refuse to answer any questions that you do not wish to answer during 
the process of filling up/interview. 
  
(7) Are there any risks or costs associated with being in the study? 
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Overall this study will give a minimum possible risk such as: 
- Feeling distressed and or anxious caused by the knowledge of your test result. 
- Embarrassment for you through the provision of your personal information 
and risky sexual behavior. 
- Inconvenience as you have to give up a time to participate in the research 
project and may need to be recalled if your test result comes up positive. 
 
(8) Are there any benefits associated with being in the study? 
 
The benefit of the project is that you learn about your HIV-STI status and received 
treatment if your tests came back positive. You may feel confident that you will 
receive proper treatment and counselling which will reduce potential harm to 
you. 
  
By following this study you will get a free molecular test of chlamydial and 
gonorrhoea infection. 
If you complete the questionnaire and sample collection you will also receive 
some money (Rp. 50,000 / 5 AUD) or mobile voucher (Rp. 50,000/5 AUD) (you 
have to choose one) as a reward for your time and effort. 
 
Further benefit for the community is by participating in this study, you will help 
the researcher to provide a good scientific data and analysis for the government 
to evaluate and build better strategies to prevent and protecting the community 
from the HIV / STI. 
 
 
(9) What will happen to information about me that is collected during the study? 
 
- Information about you in the form of laboratory result from your medical 
record and the test result from the lab in Jakarta and questionnaire will be 
used in this study. 
- Information from this study will only be accessed by the study code translator, 
the researcher himself, his supervisor, statistician for the data processing, and 
by the head doctor of the clinic for the reason of patient recall and future 
treatment.  
- All the information from the lab result will be confidential and being kept in 
your medical record in the PKR clinic and all the documents will be transferred 
into electronic document. All the questionnaire, informed consent, and 
transcript of participant id number and two by four codes will also be 
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transferred into electronic data and then will be stored in University electronic 
data storage.  
- Your positive laboratory results from the PKR clinic will be informed to you 
directly as a standard operating procedure and the result of the molecular test 
from the lab in Jakarta will be informed by the clinic’s doctor personally to you 
if it is positive after it comes back from the laboratory. 
 
By providing your consent, you are agreeing to us collecting personal information 
about you for the purposes of this research study. Your information will only be 
used for the purposes outlined in this Participant Information Statement unless 
you consent otherwise. 
 
Your information will be stored securely and your identity/information will be 
kept strictly confidential, except as required by law. Study findings may be 
published, but you will not be individually identifiable in these publications. 
 
We will keep the information we collect for this study, and we may use it in future 
projects. By providing your consent you are allowing us to use your information 
in future projects. We do not know at this stage what these other projects will 
involve. We will seek ethical approval before using the information in these future 
projects.  
 
 
(10) Can I tell other people about the study? 
 
Yes, you are welcome to tell other people about the study. 
 
(11) What if I would like further information about the study? 
 
When you have read this information, dr. Gerson Andrew Warnares will be 
available to discuss it with you further and answer any questions you may have. If 
you would like to know more at any stage of the study, please feel free to contact 
dr. Gerson Andrew Warnares (Researcher, gwar0011@uni.sydney.edu.au, 
researcher study mobile number (dr. Gerson), or local contact dr. Esty 
(+6281334748137). 
 
(12) Will I be told the results of the study? 
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You have a right to receive feedback about the overall results of this study. You 
can tell us that you wish to receive feedback by tick the relevant box on the 
consent form. This feedback will be in the form of a one-page lay summary. It will 
be about the analysis and conclusion of the prevalence of HIV/STI and their 
association with the risk behaviour. You will receive this feedback after the study 
is finished through the clinic or you can ask to be sent to your address. 
You will also receive the laboratory result if positive through clinic’s doctor. 
 
(13) What if I have a complaint or any concerns about the study? 
 
Research involving humans in Australia is reviewed by an independent group of 
people called a Human Research Ethics Committee (HREC). The ethical aspects of 
this study have been approved by the HREC of the University of Sydney [protocol 
number 2016/412]. As part of this process, we have agreed to carry out the study 
according to the National Statement on Ethical Conduct in Human Research 
(2007). This statement has been developed to protect people who agree to take 
part in research studies. 
 
If you are concerned about the way this study is being conducted or you wish to 
make a complaint to someone independent from the study, please contact the 
university using the details outlined below. Please quote the study title and 
protocol number.  
 
The Manager, Ethics Administration, University of Sydney: 
 Telephone: +61 2 8627 8176 
 Email: ro.humanethics@sydney.edu.au 
 Fax: +61 2 8627 8177 (Facsimile) 
 
Or the manager of health issue prevention unit of Jayapura City health department: 
 Telephone: +62811483863  
 
This information sheet is for you to keep 
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Appendix 2 Participant Consent Form 
 
 
 
  
Master of Philosophy 
Sydney Medical School 
  
 ABN 15 211 513 464 
 
  David Lewis   
 Professor , FRCH (UK) FAChSHM PhD 
  
Director Room 
 Western Sydney Sexual Health 
NSW 2006 AUSTRALIA 
Telephone:   +61 2 9762 5388 
Facsimile:  +61 2 97625387 
Email: david.lewis2@sydney.edu.au 
Web:http://www.sydney.edu.au/medicine/wsshc 
 
 Prevalence of HIV and STI among Women Working in Entertainment Venues (Parlours, 
Karaoke, Clubs, and Bars) in Jayapura- Indonesia  
 
PARTICIPANT CONSENT FORM 
 
 
I, ................................................................................... [PRINT NAME], agree to take part in this 
research study. 
 
In giving my consent I state that: 
 
 I understand the purpose of the study, what I will be asked to do, and any risks/benefits 
involved.  
 
 I have read the Participant Information Statement and have been able to discuss my 
involvement in the study with the researchers if I wished to do so.  
 
 The researchers have answered any questions that I had about the study and I am happy with 
the answers. 
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 I understand that being in this study is completely voluntary and I do not have to take part. 
My decision whether to be in the study will not affect my relationship with the researchers or 
anyone else at the Reproduction Health Centre (PKR) clinic in Jayapura now or in the future. 
 
 I understand that I can withdraw from the study at any time. 
 
 I understand that I may stop : filling up the questionnaire/the interview, at any time if I do not 
wish to continue, and that unless I indicate otherwise any recordings will then be erased and 
the information provided will not be included in the study. I also understand that I may refuse 
to answer any questions I do not wish to answer. 
 
 
 
 
 
 I understand that personal information about me that is collected over the course of this 
project will be stored securely and will only be used for purposes that I have agreed to. I 
understand that information about me will only be told to others with my permission, except 
as required by law. 
 
 I understand that the results of this study may be published, and that publication will not 
contain my name or any identifiable information about me. 
 
I consent to: 
  
 My laboratory result from my medical record and  YES  NO  
 additional lab result offered in the study 
 
 Receiving cervical swab for additional molecular YES  NO  
 laboratory test for gonorrhoea and chlamydia  
 
 Questionnaire   YES  NO  
 
 Having my de-identified data stored  YES  NO  
  for future project. 
 
 Being recalled by the clinic if my additional test   YES  NO  
 is positive 
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Would you like to receive feedback about the overall results of this study in a form of one-
page lay summary ?  
    YES  NO  
If you answered YES, please indicate your preferred form of feedback and address: 
 
 Through the clinic, I want it to be available in the clinic when I have my regular visit. 
 
 Postal  :     
 
 
 
................................................................... 
Signature  
 
 
 
 .............. .................................................... 
PRINT name 
 
 
.................................................................................. 
Date  
Id number : two by four code : 
 
147 
 
Appendix 3 Study questionnaire  
 
Questionnaire   
Demographic data 
- Age   :  …………………… years old 
- Marital status  :    Never married    Currently married 
 Married before   Regular partners 
 
- Pregnancy history:  Never    Previously miscarriage 
 Once 
 More than once  
- Last education :  No schooling / primary  
 Passed junior high school 
 Passed senior high school and above 
 
Risk behavior 
Duration of time exchanging sex for  :  ≤ 6 months  
personal benefits (eg. Money, shelter, food, etc)   6 – 24 months 
   
 ≥24 months 
 
- Duration in the current establishment  :  ≤ 6 months 
 ≥ 6 months 
 
- Number of client in the past week  : ……….  
- Had a boyfriend in the past year  :   Yes 
 No 
 
- Condom use with clients in the past week :  Not always  Never 
 Always  N/A (not 
applicable) 
- Condom use with boyfriend in the past months:  Not always  Never  
Id number : two by four code : 
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 Always  N/A no regular 
partner 
- Had vaginal discharge in the last 5 years    :  Yes   
No 
 
- Had syphilis before        :  Yes  
No 
 
- Drank alcohol before having sex in the past 3 months  :  Yes  
No 
 
- Visited STI clinic for check up in the past 3 months   :  
Yes  No 
 
- Had symptoms of STI in the past year     :  
Yes  No 
 
- At the last episode of vaginal discharges in the past year I :  
 Had no treatment 
 Did self-medication/ over counter drug 
 Seeking medical treatment 
 Other (traditional) 
- Tested and obtain result of HIV test in the past year   :   
Yes  No 
 
- Number of rounds presumptive treatment for STIs received in the past 6 months 
: 
 None 
 One 
 Two 
 Three 
Sexual history and recent practice  
First sexual intercourse    : ……….. y.o (age) 
Place of sexual transaction    :   Hotel  
        Motel 
        Private rent room of guess 
Id number : two by four code : 
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        House 
Price of short time encounter   :  0 – 500 k Rupiah  
>500 k – 750 k Rupiah 
>750 k – 1 million Rupiah 
>1 million Rupiah 
Receiving anal sex    :   always  
        often 
        rarely  
        never  
Using condoms while doing anal sex  :  always  
        often 
        rarely  
        never  
       Reason : ………………………………… 
Give oral sex to client    :   always  
        often 
        rarely  
        never  
Using dams while giving oral sex  :  always  
        often 
        rarely  
        never  
       Reason : …………………………….. 
Receive oral sex from the client  :  always  
        often 
        rarely  
        never 
       Reason : …………………………………………. 
Id number : two by four code : 
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Using dams while receiving oral sex  :  always  
        often 
        rarely  
        never  
       Reason : …………………………….. 
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Appendix 4 Flyer 
  
 
 
 
 
 
 
If it is you, then you are eligible to participate in our study.  
Get : 
FREE chlamydia  test  and 
 
asda 
*Only 15-25 minutes. 
 
When ? 
August-September 2016 
Where ? 
The Health Reproduction  
Center (PKR) Clinic,  
Kotaraja-Jayapura. 
What do you need to do ? 
- Read and sign the consent form 
- Fill in a study questionnaire 
- Allow a nurse to obtain an extra cervical swab. 
How to register ? 
- Put your name on the list at the receptionist, or 
- Send text message to (researcher mobile), or 
- Register during your visit 
 
Do you need more info ? Please contact : 
clinic doctor name (mobile number) 
          nurse name (mobile number) 
           researcher name (mobile number) 
 
 
 
 
 
 
mobile voucher / transport fee 
worth of Rp. 50.000 
